Track market-moving stories before they get noisy

Assenagon Asset Management S.A. grew its stake in Hewlett Packard Enterprise Company (NYSE:HPE – Free Report) by 10.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,371,297 shares of the technology company’s stock after acquiring an additional 131,297 shares during the period. Assenagon Asset Management S.A. owned 0.10% of Hewlett Packard Enterprise worth $87,612,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Barrow Hanley Mewhinney & Strauss LLC bought a new stake in Hewlett Packard Enterprise during the 2nd quarter worth about $1,027,139,000. Primecap Management Co. CA bought a new position in shares of Hewlett Packard Enterprise in the 2nd quarter valued at about $773,225,000. Legal & General Group Plc bought a new position in shares of Hewlett Packard Enterprise in the 2nd quarter valued at about $512,721,000. Elliott Investment Management L.P. grew its position in shares of Hewlett Packard Enterprise by 47.2% during the 1st quarter. Elliott Investment Management L.P. now owns 27,421,735 shares of the technology company’s stock worth $652,912,000 after buying an additional 8,790,757 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Hewlett Packard Enterprise during the 2nd quarter worth approximately $322,718,000. 80.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets Several equities analysts recently weighed in on HPE shares. Raymond James Financial increased their price objective on shares of Hewlett Packard Enterprise from $74.00 to $86.00 and gave the company an “outperform” rating in a report on Thursday, September 3rd. Loop Capital reduced their price objective on shares of Hewlett Packard Enterprise from $75.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, September 8th. Piper Sandler lifted their target price on shares of Hewlett Packard Enterprise from $57.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, October 1st. Barclays cut shares of Hewlett Packard Enterprise from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $83.00 to $77.00 in a research report on Wednesday. Finally, Wells Fargo & Company increased their price target on Hewlett Packard Enterprise from $54.00 to $63.00 and gave the company an “equal weight” rating in a research note on Thursday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $65.44.

Read Our Latest Stock Report on HPE Insiders Place Their Bets In other news, Director Gary M. Reiner sold 17,000 shares of the stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $56.91, for a total transaction of $967,470.00. Following the completion of the transaction, the director directly owned 65,072 shares in the company, valued at $3,703,247.52. This represents a 20.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Rami Rahim sold 34,456 shares of the firm’s stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $61.42, for a total value of $2,116,287.52. Following the completion of the transaction, the executive vice president owned 875,133 shares of the company’s stock, valued at $53,750,668.86. The trade was a 3.79% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 551,456 shares of company stock valued at $35,271,258 in the last three months. 0.44% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Hewlett Packard Enterprise Here are the key news stories impacting Hewlett Packard Enterprise this week:

Positive Sentiment: HPE announced a planned $75 million expansion in Chippewa Falls, Wisconsin, expected to create 75 jobs. The investment supports the company’s manufacturing and infrastructure operations, although its near-term effect on earnings is likely limited. HPE to spend $75M to expand, add 75 jobs in Chippewa Falls Positive Sentiment: Some investors remain constructive because HPE has reported record revenue, orders and backlog, while demand for traditional servers, AI systems and networking—and higher server prices—has supported recent results. HPE stock was also reported to be up substantially for the year before the latest retreat. What Was HPE Telling You Before Its Stock Ran? Neutral Sentiment: ETF selling added to short-term pressure, while some dip buyers are betting that HPE can convert its AI and server orders into revenue. However, the recent decline has raised questions about whether earlier dip-buying strategies will continue to work. ETFs Are Net Sellers of Hewlett Packard Enterprise Negative Sentiment: Barclays downgraded HPE to Equal Weight from Overweight and lowered its price target to $77 from $83. The firm questioned how quickly corporate customers will adopt AI hardware and suggested that memory-component inflation, rather than new AI deployments, may be driving server revenue growth. Why Hewlett Packard Enterprise Stock Is Trading Lower Today Negative Sentiment: Concerns over how customers will finance large AI infrastructure projects have spread across hardware stocks, including HPE, Dell and Super Micro. The resulting sector-wide selling, combined with scrutiny of HPE’s server revenue quality and adoption timeline, drove a roughly 20% decline between October 9 and October 15. AI Financing Worries Extend Hardware Selloff Hewlett Packard Enterprise Stock Performance Shares of Hewlett Packard Enterprise stock opened at $55.32 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.11 and a quick ratio of 0.72. The firm has a market cap of $73.44 billion, a price-to-earnings ratio of 28.81, a price-to-earnings-growth ratio of 0.52 and a beta of 1.39. The stock’s 50-day moving average is $59.34 and its 200-day moving average is $46.33. Hewlett Packard Enterprise Company has a one year low of $19.84 and a one year high of $73.56.

Hewlett Packard Enterprise (NYSE:HPE – Get Free Report) last issued its quarterly earnings results on Wednesday, September 2nd. The technology company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.18. Hewlett Packard Enterprise had a net margin of 6.60% and a return on equity of 15.50%. The company had revenue of $12.21 billion during the quarter, compared to analysts’ expectations of $11.97 billion. During the same period last year, the business earned $0.44 EPS. The business’s quarterly revenue was up 33.7% on a year-over-year basis. Hewlett Packard Enterprise has set its Q4 2026 guidance at 1.200-1.300 EPS and its FY 2026 guidance at 3.750-3.850 EPS. Equities analysts predict that Hewlett Packard Enterprise Company will post 3.34 earnings per share for the current fiscal year.

Hewlett Packard Enterprise Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Thursday, September 17th were given a dividend of $0.1425 per share. The ex-dividend date of this dividend was Thursday, September 17th. This represents a $0.57 annualized dividend and a yield of 1.0%. Hewlett Packard Enterprise’s payout ratio is 29.69%.

(Free Report)

Hewlett Packard Enterprise Company (NYSE:HPE) is a global technology company that provides information technology products, services and solutions for businesses, governments and other organizations. Its offerings are designed to help customers build, manage and secure data center, cloud and edge-computing environments.

HPE’s portfolio includes enterprise servers, high-performance computing systems, data storage, networking equipment, software and technology consulting services. The company also provides hybrid cloud and as-a-service solutions through HPE GreenLake, allowing customers to access and manage computing, storage, data protection and other IT capabilities through a flexible consumption model.

See Also Five stocks we like better than Hewlett Packard Enterprise Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding HPE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hewlett Packard Enterprise Company (NYSE:HPE – Free Report).

Receive News & Ratings for Hewlett Packard Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hewlett Packard Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.

Annex Advisory Services LLC grew its holdings in UnitedHealth Group Incorporated (NYSE:UNH – Free Report) by 70.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,856 shares of the healthcare conglomerate’s stock after purchasing an additional 48,279 shares during the period. Annex Advisory Services LLC’s holdings in UnitedHealth Group were worth $42,896,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. North Capital Inc. bought a new stake in UnitedHealth Group in the third quarter worth $210,000. Milestone Asset Management LLC lifted its position in shares of UnitedHealth Group by 14.4% in the third quarter. Milestone Asset Management LLC now owns 12,480 shares of the healthcare conglomerate’s stock worth $4,581,000 after buying an additional 1,570 shares during the last quarter. Detalus Advisors LLC acquired a new position in shares of UnitedHealth Group during the 3rd quarter valued at about $431,000. SLT Holdings LLC increased its holdings in shares of UnitedHealth Group by 6.1% during the 3rd quarter. SLT Holdings LLC now owns 7,328 shares of the healthcare conglomerate’s stock valued at $2,690,000 after acquiring an additional 419 shares during the last quarter. Finally, Whitener Capital Management Inc. boosted its position in UnitedHealth Group by 14.9% during the third quarter. Whitener Capital Management Inc. now owns 4,475 shares of the healthcare conglomerate’s stock worth $1,643,000 after purchasing an additional 582 shares during the period. Hedge funds and other institutional investors own 87.86% of the company’s stock.

Insider Buying and Selling at UnitedHealth Group In other news, CEO Patrick Conway sold 1,169 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $390.00, for a total transaction of $455,910.00. Following the transaction, the chief executive officer owned 15,328 shares of the company’s stock, valued at $5,977,920. This represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.19% of the stock is currently owned by insiders.

UnitedHealth Group News Roundup Here are the key news stories impacting UnitedHealth Group this week: Positive Sentiment: Q3 results and guidance exceeded expectations. UnitedHealth reported adjusted earnings of $4.69 per share versus the $4.14 consensus estimate, while revenue of $112.7 billion also topped forecasts. Management raised its 2026 adjusted EPS outlook to at least $20.50, supporting the recovery narrative. UnitedHealth Stock Moves Higher: What’s Going On? Positive Sentiment: Analyst support remains significant. JPMorgan raised its price target to $524 and maintained an “overweight” rating, while Goldman Sachs reportedly lifted its target to $506 after concluding that Medicare Advantage margin recovery is progressing faster than expected. JPMorgan Raises UnitedHealth Price Target Positive Sentiment: Potential growth areas could support 2027 and beyond. UnitedHealth’s focus on Medicare special-needs plans, expanded coverage and care-delivery operations may provide targeted growth while improving margins. Its low beta also makes UNH attractive as a defensive healthcare holding during inflation and market rotation away from technology stocks. Can UNH’s Focus on Special Needs Plans Strengthen Medicare Growth? Neutral Sentiment: Recent gains may have already priced in much of the good news. Commentary noted that the earnings beat and outlook increase were followed by questions about how durable the recovery will be, limiting the immediate upside despite bullish targets. UnitedHealth Beats on Earnings, But Investors Question Growth Path Negative Sentiment: Membership fell and medical costs remain high. Analysts are concerned that shrinking membership and elevated utilization could constrain revenue growth and margins, particularly if higher care costs persist. This is the main reason investors are questioning whether the earnings improvement can continue. UnitedHealth’s Q3 Margins Improve, But Membership Falls Negative Sentiment: Analyst views are mixed. Barclays issued a pessimistic forecast, Robert W. Baird cut its price target, and TD Cowen reiterated a “hold” rating with a $402 target, signaling limited near-term upside for some investors. UnitedHealth Group Price Performance Shares of UNH stock opened at $401.77 on Friday. The stock’s fifty day moving average is $387.07 and its 200-day moving average is $384.64. The stock has a market capitalization of $360.62 billion, a PE ratio of 19.92, a PEG ratio of 1.47 and a beta of 0.60. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 0.74. UnitedHealth Group Incorporated has a 52 week low of $255.96 and a 52 week high of $461.62.

UnitedHealth Group (NYSE:UNH – Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The healthcare conglomerate reported $4.69 EPS for the quarter, topping analysts’ consensus estimates of $4.14 by $0.55. UnitedHealth Group had a net margin of 3.53% and a return on equity of 17.95%. The firm had revenue of $112.70 billion for the quarter, compared to analyst estimates of $111.31 billion. During the same quarter in the prior year, the firm earned $2.59 EPS. The company’s revenue was down .4% on a year-over-year basis. UnitedHealth Group has set its FY 2026 guidance at 20.500- EPS. Equities research analysts expect that UnitedHealth Group Incorporated will post 20.65 EPS for the current fiscal year.

UnitedHealth Group Announces Dividend The company also recently announced a quarterly dividend, which was paid on Tuesday, September 22nd. Stockholders of record on Monday, September 14th were paid a $2.32 dividend. This represents a $9.28 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend was Monday, September 14th. UnitedHealth Group’s dividend payout ratio (DPR) is 53.00%.

Analysts Set New Price Targets A number of analysts have recently weighed in on the stock. The Goldman Sachs Group boosted their price objective on shares of UnitedHealth Group from $435.00 to $490.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Evercore raised their target price on shares of UnitedHealth Group from $400.00 to $480.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Mizuho boosted their target price on shares of UnitedHealth Group from $470.00 to $493.00 and gave the stock an “outperform” rating in a research report on Monday, July 20th. Robert W. Baird decreased their price target on shares of UnitedHealth Group from $453.00 to $427.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Oppenheimer lifted their price objective on UnitedHealth Group from $420.00 to $500.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Twenty equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $462.90.

Read Our Latest Analysis on UNH

UnitedHealth Group Company Profile (Free Report)

UnitedHealth Group Incorporated (NYSE: UNH) is a diversified health care and well-being company serving individuals, employers, health care providers and government programs. Its operations are organized primarily through UnitedHealthcare and Optum.

UnitedHealthcare provides health benefit plans and services, including employer-sponsored coverage, individual and family plans, Medicare and Medicaid offerings, and other government-supported programs. Its services include health insurance administration, pharmacy benefits and care management.

Optum provides health care services, technology and data solutions, pharmacy services, and analytics to health plans, employers, government agencies, health care providers and consumers.

Further Reading Five stocks we like better than UnitedHealth Group Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH – Free Report).

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

Banque Pictet & Cie SA lowered its stake in Moody’s Corporation (NYSE:MCO – Free Report) by 5.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,541 shares of the business services provider’s stock after selling 3,760 shares during the period. Banque Pictet & Cie SA’s holdings in Moody’s were worth $30,672,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Kestra Private Wealth Services LLC grew its holdings in shares of Moody’s by 0.3% in the first quarter. Kestra Private Wealth Services LLC now owns 6,440 shares of the business services provider’s stock worth $2,810,000 after purchasing an additional 22 shares during the last quarter. Resolute Wealth Strategies LLC lifted its holdings in shares of Moody’s by 3.8% in the 1st quarter. Resolute Wealth Strategies LLC now owns 623 shares of the business services provider’s stock worth $272,000 after buying an additional 23 shares during the period. Goelzer Investment Management Inc. lifted its holdings in shares of Moody’s by 1.2% in the 3rd quarter. Goelzer Investment Management Inc. now owns 1,949 shares of the business services provider’s stock worth $885,000 after buying an additional 23 shares during the period. Matrix Trust Co grew its position in shares of Moody’s by 1.5% during the 3rd quarter. Matrix Trust Co now owns 1,706 shares of the business services provider’s stock worth $775,000 after buying an additional 26 shares in the last quarter. Finally, Wilkerson Advisory Group LLC grew its position in shares of Moody’s by 87.1% during the 1st quarter. Wilkerson Advisory Group LLC now owns 58 shares of the business services provider’s stock worth $25,000 after buying an additional 27 shares in the last quarter. 92.11% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Moody’s Here are the key news stories impacting Moody’s this week:

Positive Sentiment: Royal Bank of Canada lowered its price target to $575 from $610 but maintained an “outperform” rating. The revised target still implies substantial upside from Moody’s recent trading level, signaling that RBC views the pullback in expectations as a valuation adjustment rather than a change in the company’s long-term outlook. Benzinga analyst ratings report Positive Sentiment: Wall Street is preparing for Moody’s third-quarter earnings report on October 21, with consensus calling for approximately $4.25 in earnings per share. Investors are focused on whether continued demand for credit ratings, research and risk-management products can sustain the company’s recent double-digit revenue growth and strong profitability. Moody’s Q3 2026 earnings preview Neutral Sentiment: Pre-earnings coverage is highlighting estimates for revenue, operating margins and other key metrics beyond headline EPS. These previews could increase volatility around the October 21 report, particularly if Moody’s delivers strong earnings but offers cautious guidance. Zacks Moody’s Q3 estimates Negative Sentiment: Jefferies reduced its Moody’s price target to $560 from $610. The cut may weigh on sentiment because it reflects more limited upside following the stock’s recent advance, although the new target remains above the current share price. Jefferies Moody’s price-target update Negative Sentiment: Additional commentary from BMO Capital Markets and other analysts has emphasized a more cautious valuation outlook, reinforcing concerns that expectations and the stock’s premium valuation leave less room for an earnings disappointment. BMO Moody’s forecast Insider Buying and Selling In other Moody’s news, CEO Robert Fauber sold 923 shares of Moody’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $455.00, for a total value of $419,965.00. Following the completion of the transaction, the chief executive officer owned 51,364 shares of the company’s stock, valued at approximately $23,370,620. The trade was a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock. Analyst Upgrades and Downgrades MCO has been the subject of several recent research reports. Royal Bank Of Canada decreased their price objective on Moody’s from $610.00 to $575.00 and set an “outperform” rating for the company in a report on Friday. Deutsche Bank Aktiengesellschaft increased their target price on shares of Moody’s from $587.00 to $594.00 and gave the stock a “buy” rating in a report on Thursday, July 23rd. The Goldman Sachs Group increased their target price on shares of Moody’s from $557.00 to $593.00 and gave the stock a “buy” rating in a report on Thursday, July 23rd. Mizuho raised their target price on shares of Moody’s from $521.00 to $530.00 and gave the company a “neutral” rating in a research report on Monday, July 27th. Finally, Citigroup restated a “buy” rating and issued a $600.00 price target (up from $565.00) on shares of Moody’s in a report on Wednesday, July 29th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $551.26.

View Our Latest Stock Report on Moody’s

Moody’s Price Performance Shares of NYSE MCO opened at $484.71 on Friday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 1.19 and a current ratio of 1.19. The company has a market cap of $83.95 billion, a PE ratio of 29.19, a P/E/G ratio of 2.49 and a beta of 1.35. The business has a 50-day simple moving average of $477.91 and a two-hundred day simple moving average of $466.64. Moody’s Corporation has a fifty-two week low of $402.28 and a fifty-two week high of $546.88.

Moody’s (NYSE:MCO – Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The business services provider reported $4.68 earnings per share for the quarter, beating the consensus estimate of $4.26 by $0.42. Moody’s had a return on equity of 80.35% and a net margin of 34.25%. The business had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.09 billion. During the same quarter in the previous year, the business earned $3.56 EPS. The company’s quarterly revenue was up 15.1% compared to the same quarter last year. Moody’s has set its FY 2026 guidance at 16.500-17.000 EPS. As a group, equities analysts expect that Moody’s Corporation will post 16.95 EPS for the current fiscal year.

Moody’s Announces Dividend The company also recently declared a quarterly dividend, which was paid on Friday, September 4th. Investors of record on Friday, August 14th were given a dividend of $1.03 per share. This represents a $4.12 annualized dividend and a yield of 0.8%. The ex-dividend date was Friday, August 14th. Moody’s’s dividend payout ratio (DPR) is currently 26.13%.

Moody’s Profile (Free Report)

Moody’s Corporation (NYSE:MCO) is a global provider of credit ratings, research, data, and analytical tools. Through Moody’s Ratings, the company evaluates the creditworthiness of companies, governments, financial institutions, and structured finance securities, offering opinions and research used by investors, issuers, and other market participants.

Through Moody’s Analytics, the company provides financial intelligence, economic research, risk assessment tools, data, and software. Its products support credit and market risk management, compliance, portfolio analysis, lending, insurance, and corporate planning.

Moody’s traces its origins to 1909, when John Moody published an analysis of railroad securities.

Further Reading Five stocks we like better than Moody’s Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?

Receive News & Ratings for Moody's Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moody's and related companies with MarketBeat.com's FREE daily email newsletter.

Banque Pictet & Cie SA raised its holdings in shares of The Charles Schwab Corporation (NYSE:SCHW – Free Report) by 4.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 145,818 shares of the financial services provider’s stock after acquiring an additional 5,582 shares during the quarter. Banque Pictet & Cie SA’s holdings in Charles Schwab were worth $14,252,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. USS Investment Management Ltd grew its position in shares of Charles Schwab by 4.6% during the first quarter. USS Investment Management Ltd now owns 288,035 shares of the financial services provider’s stock valued at $27,068,000 after purchasing an additional 12,789 shares in the last quarter. Whittier Trust Co. increased its stake in Charles Schwab by 3.9% in the 1st quarter. Whittier Trust Co. now owns 384,881 shares of the financial services provider’s stock worth $35,790,000 after acquiring an additional 14,538 shares during the last quarter. Financial Advisory Partners LLC bought a new stake in Charles Schwab in the 1st quarter worth approximately $3,199,000. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Charles Schwab by 112.0% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 89,498 shares of the financial services provider’s stock worth $8,411,000 after acquiring an additional 47,281 shares in the last quarter. Finally, Private Wealth Partners LLC raised its holdings in shares of Charles Schwab by 91.9% during the 1st quarter. Private Wealth Partners LLC now owns 204,248 shares of the financial services provider’s stock worth $19,195,000 after acquiring an additional 97,829 shares in the last quarter. 84.38% of the stock is currently owned by hedge funds and other institutional investors.

Charles Schwab Stock Down 2.5% NYSE:SCHW opened at $91.81 on Friday. The Charles Schwab Corporation has a fifty-two week low of $83.96 and a fifty-two week high of $114.53. The stock has a market capitalization of $158.77 billion, a P/E ratio of 15.67, a P/E/G ratio of 0.80 and a beta of 0.79. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.64 and a current ratio of 0.64. The company’s 50-day simple moving average is $104.50 and its 200-day simple moving average is $98.15.

Charles Schwab (NYSE:SCHW – Get Free Report) last posted its earnings results on Thursday, October 15th. The financial services provider reported $1.69 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $0.03. The company had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.18 billion. Charles Schwab had a net margin of 39.33% and a return on equity of 25.79%. Charles Schwab’s revenue for the quarter was up 16.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.31 earnings per share. On average, equities analysts anticipate that The Charles Schwab Corporation will post 6.45 earnings per share for the current fiscal year. Charles Schwab Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Friday, August 28th. Stockholders of record on Friday, August 14th were given a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.4%. Charles Schwab’s dividend payout ratio is presently 23.27%.

Analyst Upgrades and Downgrades A number of research analysts have recently commented on SCHW shares. Compass Point assumed coverage on Charles Schwab in a research report on Monday, August 3rd. They set a “buy” rating and a $135.00 target price for the company. The Goldman Sachs Group reaffirmed a “buy” rating and set a $117.00 price target on shares of Charles Schwab in a research note on Friday. Truist Financial set a $115.00 price target on shares of Charles Schwab in a research note on Friday. Weiss Ratings upgraded shares of Charles Schwab from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, September 10th. Finally, Jefferies Financial Group set a $120.00 price objective on shares of Charles Schwab in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $118.95.

Read Our Latest Stock Report on SCHW

Trending Headlines about Charles Schwab Here are the key news stories impacting Charles Schwab this week:

Positive Sentiment: Schwab reported adjusted third-quarter EPS of $1.69, exceeding the $1.66 analyst consensus, while revenue rose 16.9% year over year to a record $7.17 billion. Net income increased 23% to approximately $2.91 billion. Charles Schwab Stock Is Falling Friday: What’s Going On? Positive Sentiment: Client momentum remained a major strength: core net new assets reached a record $190.4 billion, up 38% year over year, total client assets climbed to $13.33 trillion, and the company added roughly 1.2 million brokerage accounts. Higher trading activity, lending, and net interest revenue supported the quarter. Schwab Delivers Record Net New Assets & Earnings Positive Sentiment: Analysts remain broadly constructive. JPMorgan reaffirmed an “overweight” rating with a $147 price target, while Citizens JMP maintained “market outperform” with a $120 target. Schwab is also expanding AI tools, tax-aware products, cryptocurrency services, and prediction-market capabilities, potentially creating additional engagement and revenue opportunities. Neutral Sentiment: Management said clients using AI-enabled trading tools are holding more cash rather than withdrawing funds, which could support Schwab’s deposit and lending franchise. However, the long-term financial impact of these new products remains unproven. Negative Sentiment: Revenue of $7.17 billion was slightly below the approximately $7.18 billion consensus estimate. Analysts characterized the quarter as “somewhat low quality,” citing less impressive net-interest-revenue trends and the possibility that strong market activity, rather than purely organic improvement, drove results. Charles Schwab’s Q3 Print was Somewhat Low Quality Negative Sentiment: Schwab indicated that full-year 2026 revenue and net-interest-margin growth could land at the lower end of its previous ranges. Truist reduced its price target, and some investors appear to be taking profits after the stock’s earlier gains. Insider Buying and Selling at Charles Schwab In other news, insider Dennis Howard sold 28,000 shares of the firm’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $105.01, for a total value of $2,940,280.00. Following the completion of the sale, the insider owned 10,470 shares of the company’s stock, valued at $1,099,454.70. This trade represents a 72.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Peter J. Morgan III sold 6,952 shares of the business’s stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $102.03, for a total value of $709,312.56. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 645,582 shares of company stock valued at $69,553,935. Corporate insiders own 6.30% of the company’s stock.

Charles Schwab Profile (Free Report)

Charles Schwab Corporation (NYSE:SCHW) is a financial services company that provides brokerage, investment, banking and wealth management services to individual investors, employers, institutions and independent investment advisors. Its offerings include online and mobile trading, securities brokerage, retirement accounts, financial planning, portfolio management, banking products, research and access to mutual funds and exchange-traded funds.

The company operates through businesses including Schwab Brokerage, Schwab Wealth Advisory, Schwab Asset Management and Charles Schwab Bank.

Read More Five stocks we like better than Charles Schwab Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding SCHW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Charles Schwab Corporation (NYSE:SCHW – Free Report).

Receive News & Ratings for Charles Schwab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles Schwab and related companies with MarketBeat.com's FREE daily email newsletter.

First Citizens Bank & Trust Co. purchased a new stake in shares of BXP, Inc. (NYSE:BXP – Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 11,033 shares of the real estate investment trust’s stock, valued at approximately $674,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Janus Henderson Group PLC grew its position in BXP by 481.7% during the first quarter. Janus Henderson Group PLC now owns 69,907 shares of the real estate investment trust’s stock valued at $3,626,000 after buying an additional 57,889 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in BXP during the second quarter worth about $6,774,000. Arrowstreet Capital Limited Partnership purchased a new stake in BXP during the first quarter worth about $4,938,000. Bank of New York Mellon Corp purchased a new stake in BXP during the second quarter worth about $63,769,000. Finally, Hsbc Holdings PLC raised its position in BXP by 18.9% in the fourth quarter. Hsbc Holdings PLC now owns 776,982 shares of the real estate investment trust’s stock worth $52,438,000 after acquiring an additional 123,301 shares during the period. 98.72% of the stock is owned by hedge funds and other institutional investors.

BXP Stock Down 0.9% Shares of NYSE:BXP opened at $59.17 on Friday. The firm has a fifty day moving average price of $64.56 and a two-hundred day moving average price of $63.18. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.91 and a quick ratio of 3.91. BXP, Inc. has a one year low of $49.72 and a one year high of $74.96. The company has a market cap of $9.45 billion, a price-to-earnings ratio of 8.69, a PEG ratio of 2.53 and a beta of 1.03.

BXP (NYSE:BXP – Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The real estate investment trust reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.03. BXP had a net margin of 8.44% and a return on equity of 3.88%. The firm had revenue of $895.70 million for the quarter, compared to analysts’ expectations of $858.07 million. During the same quarter in the prior year, the firm posted $1.71 earnings per share. The business’s quarterly revenue was up 3.1% on a year-over-year basis. BXP has set its FY 2026 guidance at 6.990-7.050 EPS and its Q3 2026 guidance at 1.800-1.820 EPS. Analysts anticipate that BXP, Inc. will post 7.02 EPS for the current fiscal year. BXP Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date is Wednesday, September 30th. BXP’s dividend payout ratio (DPR) is 150.54%.

Wall Street Analyst Weigh In A number of research firms have weighed in on BXP. JPMorgan Chase & Co. boosted their target price on shares of BXP from $79.00 to $87.00 and gave the company an “overweight” rating in a research note on Tuesday, August 25th. Weiss Ratings reissued a “hold (c)” rating on shares of BXP in a research report on Friday, October 2nd. Piper Sandler decreased their price target on shares of BXP from $88.00 to $72.00 and set an “overweight” rating for the company in a research note on Monday, October 12th. Barclays boosted their target price on BXP from $65.00 to $79.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Finally, Truist Financial upped their price target on BXP from $64.00 to $68.00 and gave the company a “hold” rating in a research report on Wednesday, September 9th. Ten research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $73.00.

Get Our Latest Analysis on BXP

BXP Company Profile (Free Report)

BXP, Inc (NYSE:BXP), formerly known as Boston Properties, is a real estate investment trust that owns, develops, acquires and manages primarily office properties. The company focuses on high-quality commercial real estate in major U.S. business markets and serves corporate tenants across a range of industries.

The company’s portfolio includes office buildings, mixed-use developments and life science properties, as well as select residential assets. BXP also provides property management, leasing and development services associated with its real estate holdings.

Read More Five stocks we like better than BXP Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding BXP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BXP, Inc. (NYSE:BXP – Free Report).

Receive News & Ratings for BXP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BXP and related companies with MarketBeat.com's FREE daily email newsletter.

Assenagon Asset Management S.A. raised its stake in Atmos Energy Corporation (NYSE:ATO – Free Report) by 208.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 507,818 shares of the utilities provider’s stock after buying an additional 342,962 shares during the period. Assenagon Asset Management S.A. owned about 0.30% of Atmos Energy worth $79,443,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ATO. BlackRock Inc. bought a new stake in shares of Atmos Energy in the 2nd quarter worth approximately $2,624,975,000. Bank of America Corp DE purchased a new position in shares of Atmos Energy in the second quarter worth about $720,212,000. Deutsche Bank AG purchased a new position in Atmos Energy in the 2nd quarter worth approximately $431,677,000. Legal & General Group Plc purchased a new position in Atmos Energy in the 2nd quarter worth approximately $276,558,000. Finally, GQG Partners LLC bought a new stake in Atmos Energy in the second quarter valued at approximately $202,443,000. Institutional investors own 90.17% of the company’s stock.

Atmos Energy Price Performance Shares of Atmos Energy stock opened at $167.48 on Friday. The stock’s fifty day moving average is $164.05 and its 200 day moving average is $173.16. The stock has a market cap of $28.30 billion, a P/E ratio of 19.94, a P/E/G ratio of 2.65 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.73 and a current ratio of 0.81. Atmos Energy Corporation has a one year low of $154.72 and a one year high of $192.51.

Atmos Energy (NYSE:ATO – Get Free Report) last released its earnings results on Wednesday, August 5th. The utilities provider reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.08. The company had revenue of $879.06 million for the quarter, compared to analysts’ expectations of $900.82 million. Atmos Energy had a net margin of 28.50% and a return on equity of 9.67%. During the same quarter last year, the business earned $1.16 EPS. Atmos Energy has set its FY 2026 guidance at 8.400-8.500 EPS. Sell-side analysts anticipate that Atmos Energy Corporation will post 8.47 earnings per share for the current year. Atmos Energy Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Monday, August 24th were paid a dividend of $1.00 per share. The ex-dividend date was Monday, August 24th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.4%. Atmos Energy’s payout ratio is 47.62%.

Insiders Place Their Bets In other news, Director William Ware bought 300 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was bought at an average price of $167.59 per share, with a total value of $50,277.00. Following the acquisition, the director owned 488 shares of the company’s stock, valued at approximately $81,783.92. This represents a 159.57% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.43% of the company’s stock.

Wall Street Analyst Weigh In ATO has been the subject of a number of analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of Atmos Energy in a research note on Friday, August 28th. Morgan Stanley cut their target price on shares of Atmos Energy from $190.00 to $179.00 and set an “equal weight” rating on the stock in a report on Friday, September 18th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $180.00 price target (down from $198.00) on shares of Atmos Energy in a report on Friday, September 11th. Jefferies Financial Group lowered their price target on shares of Atmos Energy from $173.00 to $167.00 and set a “hold” rating for the company in a report on Thursday, October 1st. Finally, Argus reissued a “buy” rating and issued a $185.00 target price on shares of Atmos Energy in a research note on Tuesday, October 6th. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, Atmos Energy has a consensus rating of “Hold” and an average price target of $183.00.

Check Out Our Latest Stock Report on Atmos Energy

About Atmos Energy (Free Report)

Atmos Energy Corporation is a regulated natural gas distribution and pipeline company headquartered in Dallas, Texas. The company delivers natural gas to residential, commercial, industrial and institutional customers and is one of the largest natural gas distributors in the United States.

Atmos Energy operates through two primary businesses: natural gas distribution and pipeline and storage operations. Its distribution activities include acquiring, transporting, storing and delivering natural gas, while its pipeline operations provide transportation and storage services and support the company’s distribution network.

The company serves customers across eight states, including Texas, Louisiana, Mississippi, Colorado, Kansas, Kentucky, Tennessee and Virginia.

Featured Articles Five stocks we like better than Atmos Energy Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?

Receive News & Ratings for Atmos Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atmos Energy and related companies with MarketBeat.com's FREE daily email newsletter.

New York, New York--(Newsfile Corp. - October 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Yiren Digital Ltd. (NYSE: YRD) resulting from allegations that Yiren may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Yiren securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/yiren-digital-ltd/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On October 12, 2026, Yiren issued a press release entitled "Yiren Digital Provides Update on Its CEO and Operations." The press release stated that Yired had " became aware of a police notice published on October 12, 2026, stating that Mr. Ning Tang, the Company's Executive Chairman and Chief Executive Officer, had been subject to criminal compulsory measures in connection with an investigation involving certain affiliates of the Company's controlling shareholder."

On this news, Yiren American Depositary Shares fell 44% on October 12, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319489

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

(This is the Warren Buffett Watch newsletter, news and analysis on all things Warren Buffett and Berkshire Hathaway. You can sign up here to receive it every Friday evening in your inbox.)

Berkshire Hathaway shares closed Friday at their highest level since Warren Buffett told shareholders at the May 2025 annual meeting he planned to step down as CEO at the end of that year.

The day before that Saturday surprise, both the Class A and Class B shares had closed at all-time highs.

Over the next three months, they lost more than 14% of their value as investors worried a "Buffett premium" was dissolving.

It's been more than a year since their post-meeting low in August of 2025, and the recovery has not been a straight line, but BRK.A ended Friday at $798,000, just 1.4% below its all-time closing high of $809,350.

The B shares finished at $532.02, also 1.4% under their all-time closing high of $539.80.

A loss Thursday broke a 10-session winning streak that added 5% to Berkshire's stock prices but they rebounded with gains of more than 1% Friday.

CNBC Pro thinks investors may be happy Berkshire is spending some of its big cash pile under CEO Greg Abel, with $4.5 billion of buybacks in Q2, investments in Alphabet, Taylor Morrison Home, Lennar, (although there haven't been any buys of that stock since October 2), and now, Bending Spoons. (More on that below).

It also notes Keefe, Bruyette & Woods analyst Meyer Shields believes higher short-term interest rates are helping to lift the shares.

Berkshire still has roughly $360 billion in cash, "a good symbol of continued patience under the new CEO," and those higher rates mean "they'll be making more money" on that money.

In addition, its insurance operations have benefited from a quiet hurricane season so far.

Higher oil prices are good for its $19 billion stake in Chevron, which closed Friday at an all-time high after gaining almost 36% since the start of July. Berkshire's energy-related subsidiaries are also getting a tailwind.

And recently, Berkshire may be getting a boost as investors shift away from high-flying AI and tech stocks and turn to "old" economy names.

For example, Coca-Cola, a long-time Buffett favorite and now a $37.6 billion holding, also closed Friday at an all-time high, perhaps with some extra help from KFC's switch from Pepsi to Coke. It's up 34% year-to-date.

Berkshire's position has gained $2.4 billion since last Friday, overtaking Alphabet to become the third largest stake in its portfolio. (See the full top 10 below.)

Berkshire's B shares have cut their June 1 deficit of 17.5 percentage points versus the S&P 500 by almost two-thirds.

They are now 6.0 percentage points behind the benchmark for the year.

Atypical bet on 'buzzy' Italian tech company is big win ... so farBerkshire Hathaway's surprising bet of close to $1 billion on Bending Spoons is paying off big, at least in the short term.

The Italian company, which began trading on Nasdaq in the U.S. in July, buys cast-off internet names like AOL, Evernote, and Vimeo, uses AI to cut costs, and deploys the savings to make more acquisitions.

In late July, CNBC Pro said, "Wall Street is buzzing," and "analysts ... see big gains ahead."

The tech stock is decidedly not a typical Berkshire value play, trading at a large multiple to its earnings.

But before Wall Street's open Wednesday morning, a Bending Spoons news release revealed Berkshire is investing a "further" $330 million in the company by purchasing 10 million newly issued shares at $33 per share in a private placement.

That was already an almost 12% discount from Tuesday's closing price of $37.86 and the news sent Bending Spoons shares even higher.

They hit an intraday high of $58.56 before closing up 41% at $53.46 on Wednesday. 

Bending Spoons shares are up 24.3% over the three trading days since the revelation, after giving up a chunk of their earlier gains in Friday's tech sell-off to end at $47.07.

That's a solid 42.6% higher than Berkshire's $33 purchase price for a profit, on paper, of nearly $141 million.

But what's that "further" in Bending Spoon's statement?

The release also disclosed, apparently for the first time, that Berkshire invested $600 million at Bending Spoon's IPO more than three months ago.

The release doesn't specify how many shares Berkshire bought in July, and Bending Spoons wouldn't confirm my math, but assuming Berkshire paid the $29 per share IPO price, that initial purchase would have been almost 20.7 million shares.

That puts Berkshire's holding now at close to 30.7 million shares, which would be worth more than $1.4 billion at Friday's close, a gain of 55.3% for its overall investment of $930 million.

watch now

Bending Spoon's release also says the "new investment brings Berkshire Hathaway's ownership to 4%."

The company told me in an email it hasn't "specifically disclosed" how many outstanding shares it has now, "but we had 635 million fully diluted weighted average shares outstanding in Q2, we issued 34 million shares as part of the IPO, and we will be issuing an additional 10 million as part of this transaction."

Using those numbers, Berkshire's presumed 30.7 million shares are a 4.5% stake, and that's what I've put in the Berkshire Portfolio Tracker for now.

We may learn more next month about exactly how many shares Berkshire bought in the IPO when its portfolio snapshot as of September 30 is due to be disclosed.

Another unknown: who at Berkshire made the call to take a stake in Bending Spoons.

watch now

Bending Spoons CEO and Co-Founder Luca Ferrari shares Wall Street's enthusiasm about Berkshire's investments, saying in the news release the Omaha company "has been among the finest and most respected capital allocators in the world, and is a longstanding inspiration for Bending Spoons."

Morningstar's Greggory Warren (who was one of the designated analyst questioners at Berkshire shareholders meetings from 2014 to 2019) writes the Bending Spoons buy, along with Berkshire's now $36 billion stake in Alphabet, show "the firm is finally moving out of its comfort zone to find places to put capital to work, which should be viewed as a positive for long-term investors."

At Barron's, Andrew Bary says, "Many Berkshire holders would like to see the company invest more heavily in stocks given the company's $350 billion-plus in cash, but Bending Spoons was a surprise" given its high valuation.

BUFFETT & BERKSHIRE AROUND THE INTERNETHIGHLIGHTS FROM CNBC'S BUFFETT ARCHIVE'I am one-quarter Coca-Cola' (2015)Warren Buffett defends Coca-Cola, a big and long-time Berkshire Hathaway holding, against health concerns over sugary beverages.

WARREN BUFFETT: Yeah well — people have been drinking Coca-Cola since 1886, so I imagine that there's been some — 

I don't know of any study that's been made on the lifetime of heavy users of Coca-Cola versus people who drink nothing but water.

But speaking for myself, I'm 84, literally one-quarter of all the calories I've consumed in the last 30 years have been Coca-Cola. And I don't see how anybody can feel any better than I feel. 

I am one-quarter Coca-Cola, and I can tell you, I haven't missed a day of work, you know — since I had the prostate cancer — radiation — three years ago. And I don't think the prostate cancer was caused (laughs) by Coca-Cola.

So — I — and all my friends drink it like crazy.

So there's 1.9 billion eight-ounce servings of Coca-Cola products sold around the world today, and there will be more than 1.9 billion a year from now, and more than that five years from now, and more than that ten years from now. 

And that's been true.  And some people will like other things, and — and if they like broccoli and Brussels sprouts, God bless them, you know, but don't invite me for dinner.  (Laughter)

BERKSHIRE STOCK WATCHFour weeks

Twelve months

BRK.A stock price: $798,000.00

BRK.B stock price: $532.02

BRK.B P/E (TTM): 13.38

Berkshire market capitalization: $1,138,885,966,355

Berkshire Cash as of June 30: $365.5 billion (Down 8.0% from March 31)

Excluding Rail Cash and Subtracting T-Bills Payable: $359.2 billion (Down 3.8% from March 31)

Berkshire repurchased $4.5 billion of its shares in Q2 2026.

BERKSHIRE'S TOP EQUITY HOLDINGS - Oct. 16, 2026Berkshire's top holdings of disclosed publicly traded stocks in the U.S. and Japan, by market value, based on the latest closing prices.

Holdings are as of June 30, 2026, as reported in Berkshire Hathaway's 13F filing on August 14, 2026, except for:

Mitsubishi, which is as of April 30, 2026The full list of holdings and current market values is available from CNBC.com's Berkshire Hathaway Portfolio Tracker.

QUESTIONS OR COMMENTSPlease send any questions or comments about the newsletter to me at [email protected]. (Sorry, but we don't forward questions or comments to Buffett himself.)

If you aren't already subscribed to this newsletter, you can sign up here.

Also, Buffett's annual letters to shareholders are highly recommended reading. There are collected here on Berkshire's website.

-- Alex Crippen, Editor, Warren Buffett Watch

A childless candy maker secretly handed his fortune to orphans in 1918, and the legal structure he chose still controls one of America's biggest snack companies today. Wealthy donors quietly use a version of the same playbook, but the fine…

In 1918, a childless candy maker quietly moved a large block of company stock into a trust for orphans. He told almost no one.

According to Philanthropy Roundtable, Milton Hershey placed about $60 million of Hershey (NYSE:HSY | HSY Price Prediction) stock into the trust in November 1918. For scale, Coca-Cola (NYSE:KO) sold for $25 million that same year. The foundation went back further. Hershey Trust Company was chartered on April 28, 1905, and in 1909 Milton and Catherine Hershey signed a deed of trust for what was then the Hershey Industrial School. Today it is the Milton Hershey School.

A Century-Old Trust Still Controls a Snack Giant
The Milton Hershey School and School Trust’s Form 990 for the fiscal year ending July 2025 shows total assets of about $23.6 billion and net assets of about $23.3 billion. That total covers far more than Hershey stock, and it changes from year to year. Total assets stood at $23.4 billion in July 2024 and $24.2 billion in July 2023.

The trust owns almost all of the Class B stock of Hershey. Bloomberg reported on December 11, 2024 that those shares carried roughly 80% of the company’s voting power. Hershey’s proxy calls the trust company, acting as trustee, the controlling shareholder. As of March 6, 2026, it held 54,612,012 Class B shares, and each one can be converted into a share of common stock. The trust turned away a takeover approach from Mondelez International (NASDAQ:MDLZ) in 2024 and blocked another in 2016.

He Made America’s Orphans His Heirs
Hershey said he had no heirs, so he decided to make the orphan boys of the United States his heirs. He kept the gift private until a 1923 New York Times interview, given at age 66. When he died in 1945, he owned little beyond his home and its furniture. The school serves low-income students. In 2021, ProPublica reported fiscal 2020 figures of about 2,100 students and roughly $90,000 in spending per student per year.

A trust like this does three things. It separates the assets from the donor, ties them to a stated purpose, and keeps them working across generations. The donor gives the assets away for good.

What Today’s Donors Use Instead
The closest modern comparison is a private foundation, though it is a different legal vehicle from Hershey’s 1909 deed of trust. The donor picks the board and the causes, and the foundation can fund international grants, scholarships and direct aid. A donor-advised fund offers less flexibility but allows anonymous gifts. Foundation giving is public.

Based on 2021 reporting, donors can deduct cash gifts to a private foundation up to 30% of adjusted gross income and publicly traded securities up to 20%, with a five-year carryover. Those limits may have changed since. Private foundations must also distribute at least 5% of their assets each year and pay a 1.39% excise tax on net investment income.

Setup Costs Run Well Past a Few Thousand Dollars
Wylie Advisory estimates that attorney-drafted formation documents cost $3,000 to $10,000. The “few thousand dollars” in the headline refers only to the low end of that drafting work. The IRS Form 1023 filing fee is $600. Crewe Foundation Services puts typical total startup costs at $5,000 to $20,000, while American Endowment Foundation says private attorneys often charge $7,500 to $25,000 for the state and federal filings. Wylie estimates annual operating costs of $5,000 to $30,000 or more, not counting investment management fees.

The firm also says many advisors want $3 million to $5 million in assets before recommending a foundation. All of these figures are advisory-firm estimates. A donor-advised fund is the cheaper route. Anyone considering either option should have an estate or tax attorney confirm current costs and limits.

Even Hershey’s Trust Gets Policed
In 1963, $50 million, about 20% of the endowment, was allocated to create the Milton S. Hershey Medical Center. Courts later blocked attempts to allocated more. In 2002, the trust voted to explore selling the company, and Pennsylvania’s attorney general won a court injunction.

After bids came in, the trustee voted 10 to 7 on September 17, 2002 to turn down them, according to Gadsden. The trust then agreed to notify the attorney general in advance and get court approval before any future sale. In 2016, state regulators sought the removal of several board members. The lesson for donors is that the governing document has to spell out retention, sale and oversight if the original intent is going to last.

Hershey had no heirs, so he chose some. Watch whether court and attorney general oversight keeps that intent intact.

Contact [email protected] for any questions or corrections.

First Citizens Bank & Trust Co. decreased its holdings in shares of nVent Electric PLC (NYSE:NVT – Free Report) by 63.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,594 shares of the company’s stock after selling 9,905 shares during the period. First Citizens Bank & Trust Co.’s holdings in nVent Electric were worth $897,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in NVT. Sequoia Financial Advisors LLC raised its stake in shares of nVent Electric by 16.8% during the second quarter. Sequoia Financial Advisors LLC now owns 76,540 shares of the company’s stock worth $12,982,000 after purchasing an additional 11,033 shares during the last quarter. State Street Corp lifted its holdings in shares of nVent Electric by 4.9% during the second quarter. State Street Corp now owns 5,313,122 shares of the company’s stock worth $901,159,000 after purchasing an additional 250,248 shares during the period. Alua Capital Management LP acquired a new stake in shares of nVent Electric during the first quarter worth $27,394,000. Engineers Gate Manager LP grew its position in nVent Electric by 327.1% in the 2nd quarter. Engineers Gate Manager LP now owns 33,538 shares of the company’s stock valued at $5,688,000 after buying an additional 25,686 shares during the last quarter. Finally, Corient Private Wealth LP grew its position in nVent Electric by 96.0% in the 2nd quarter. Corient Private Wealth LP now owns 36,357 shares of the company’s stock valued at $6,167,000 after buying an additional 17,806 shares during the last quarter. Institutional investors and hedge funds own 90.05% of the company’s stock.

Insider Transactions at nVent Electric In related news, CEO Beth Wozniak sold 46,261 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $164.42, for a total value of $7,606,233.62. Following the sale, the chief executive officer directly owned 55,612 shares in the company, valued at $9,143,725.04. The trade was a 45.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Randolph A. Wacker sold 22,525 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $164.62, for a total transaction of $3,708,065.50. Following the completion of the sale, the chief accounting officer directly owned 27,441 shares in the company, valued at approximately $4,517,337.42. The trade was a 45.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 74,644 shares of company stock valued at $12,276,886 in the last 90 days. 1.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets A number of equities analysts have commented on the stock. Clear Str upgraded shares of nVent Electric to a “strong-buy” rating in a research report on Monday, July 13th. Zacks Research downgraded shares of nVent Electric from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. The Goldman Sachs Group reiterated a “buy” rating and set a $200.00 price target on shares of nVent Electric in a research note on Saturday, August 1st. BMO Capital Markets assumed coverage on shares of nVent Electric in a report on Sunday, October 4th. They set an “outperform” rating and a $212.00 price target for the company. Finally, Wells Fargo & Company initiated coverage on shares of nVent Electric in a report on Thursday, September 24th. They set an “equal weight” rating and a $182.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, nVent Electric has a consensus rating of “Buy” and an average price target of $200.81. Check Out Our Latest Report on NVT

nVent Electric Stock Performance NYSE:NVT opened at $142.11 on Friday. The firm’s fifty day simple moving average is $158.96 and its 200-day simple moving average is $156.24. nVent Electric PLC has a fifty-two week low of $93.22 and a fifty-two week high of $184.64. The company has a quick ratio of 1.33, a current ratio of 1.80 and a debt-to-equity ratio of 0.37. The stock has a market cap of $23.00 billion, a PE ratio of 38.83, a price-to-earnings-growth ratio of 0.79 and a beta of 1.35.

nVent Electric (NYSE:NVT – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.16 by $0.29. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.26 billion. nVent Electric had a return on equity of 18.85% and a net margin of 12.38%. The company’s quarterly revenue was up 52.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.86 EPS. nVent Electric has set its Q3 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.000-5.100 EPS. Analysts expect that nVent Electric PLC will post 5.13 earnings per share for the current fiscal year.

nVent Electric Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 23rd will be paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, October 23rd. nVent Electric’s payout ratio is 22.95%.

About nVent Electric (Free Report)

nVent Electric plc is a global provider of electrical connection and protection solutions. The company designs and manufactures products that help protect, connect and manage electrical, electronic and critical infrastructure systems in industrial, commercial, data center, energy, transportation and other applications.

Its portfolio includes electrical and electronic enclosures, cable management systems, fastening and support products, grounding and bonding solutions, busbar and power distribution equipment, surge protection products, and thermal management systems.

Featured Stories Five stocks we like better than nVent Electric Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding NVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for nVent Electric PLC (NYSE:NVT – Free Report).

Receive News & Ratings for nVent Electric Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for nVent Electric and related companies with MarketBeat.com's FREE daily email newsletter.

Covington Investment Advisors Inc. boosted its position in shares of NVIDIA Corporation (NASDAQ:NVDA – Free Report) by 2.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 163,112 shares of the computer hardware maker’s stock after purchasing an additional 3,413 shares during the quarter. NVIDIA makes up 4.2% of Covington Investment Advisors Inc.’s portfolio, making the stock its 4th biggest holding. Covington Investment Advisors Inc.’s holdings in NVIDIA were worth $32,637,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of NVDA. Jupiter Topco LLC acquired a new stake in shares of NVIDIA in the second quarter valued at approximately $16,156,076,000. Van ECK Associates Corp raised its position in shares of NVIDIA by 34.7% in the 2nd quarter. Van ECK Associates Corp now owns 75,849,721 shares of the computer hardware maker’s stock worth $15,176,771,000 after buying an additional 19,522,304 shares during the period. Amundi raised its position in shares of NVIDIA by 10.4% in the 1st quarter. Amundi now owns 133,768,018 shares of the computer hardware maker’s stock worth $23,329,141,000 after buying an additional 12,575,177 shares during the period. SEB Asset Management AB purchased a new position in shares of NVIDIA in the 1st quarter worth $1,692,807,000. Finally, Employees Provident Fund Board acquired a new position in NVIDIA in the fourth quarter valued at $1,243,336,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

Key Headlines Impacting NVIDIA Here are the key news stories impacting NVIDIA this week:

Positive Sentiment: New RTX Spark laptops expand NVIDIA’s addressable market. Systems from ASUS, Dell, HP, Lenovo, Microsoft and MSI are now available starting at $2,599, combining Blackwell graphics, up to 128GB of memory and local AI capabilities. The launch could create a new consumer and developer revenue stream beyond data centers. NVIDIA RTX Spark PCs Available Today Positive Sentiment: Automotive and enterprise adoption continues. Volvo expanded its partnership with NVIDIA for automated-driving systems, while Adobe is integrating NVIDIA technology across Photoshop, Premiere and other creative tools. These agreements support longer-term demand for NVIDIA hardware and software. Volvo Cars expands automated driving partnership Positive Sentiment: Supply-chain investment and customer deployments remain strong. Taiwan is reportedly considering as much as $4 billion for Texas industrial parks serving NVIDIA suppliers, and customers continue deploying Blackwell systems. The developments reinforce demand, although they may take time to affect revenue. Taiwan Texas industrial parks Neutral Sentiment: NVIDIA is broadening its software and AI-model ecosystem. Paid offerings such as AI Enterprise and Mission Control, along with Nemotron open models and partnerships with AI startups, could make earnings less dependent on hardware. However, the articles provide no near-term financial contribution. Negative Sentiment: AI financing concerns are the main pressure. CoreWeave’s debt has reportedly traded at distressed yields, raising questions about whether highly leveraged customers can continue funding data-center expansion. Higher Treasury yields and inflation concerns are also making large AI projects more expensive. CoreWeave financing worries Negative Sentiment: Investors are questioning AI growth expectations. OpenAI’s reported $50 billion revenue run rate was below the roughly $68 billion previously anticipated, prompting concern that AI demand may mature more slowly. Microsoft’s development of custom Maia chips also highlights the risk of customers developing alternatives to NVIDIA GPUs. OpenAI revenue expectations Negative Sentiment: Reported insider selling adds a sentiment overhang. Recent data showed NVIDIA insiders made numerous sales and no open-market purchases over the past six months, though such transactions may reflect planned diversification rather than a change in business outlook. Insider Activity at NVIDIA In other news, Director Mark A. Stevens sold 622,239 shares of NVIDIA stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $231.62, for a total value of $144,122,997.18. Following the transaction, the director owned 2,336,531 shares of the company’s stock, valued at $541,187,310.22. This trade represents a 21.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy S. Teter sold 30,460 shares of the firm’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $222.80, for a total value of $6,786,488.00. Following the completion of the transaction, the executive vice president directly owned 2,687,660 shares of the company’s stock, valued at approximately $598,810,648. This trade represents a 1.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,766,118 shares of company stock valued at $399,450,353 over the last ninety days. Insiders own 3.94% of the company’s stock. NVIDIA Stock Down 1.4% Shares of NVIDIA stock opened at $214.13 on Friday. The company has a quick ratio of 3.85, a current ratio of 4.59 and a debt-to-equity ratio of 0.14. NVIDIA Corporation has a fifty-two week low of $164.27 and a fifty-two week high of $243.37. The business has a 50-day moving average price of $223.20 and a 200 day moving average price of $211.10. The firm has a market cap of $5.16 trillion, a P/E ratio of 31.48, a P/E/G ratio of 1.67 and a beta of 2.22.

NVIDIA (NASDAQ:NVDA – Get Free Report) last released its quarterly earnings data on Wednesday, August 26th. The computer hardware maker reported $2.22 earnings per share for the quarter, topping analysts’ consensus estimates of $2.09 by $0.13. The business had revenue of $96.22 billion for the quarter, compared to analysts’ expectations of $92.27 billion. NVIDIA had a net margin of 63.66% and a return on equity of 96.04%. The company’s revenue for the quarter was up 105.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.05 EPS. On average, sell-side analysts forecast that NVIDIA Corporation will post 9.27 earnings per share for the current fiscal year.

NVIDIA declared that its board has approved a stock repurchase plan on Monday, September 28th that permits the company to buy back $150.00 billion in outstanding shares. This repurchase authorization permits the computer hardware maker to purchase up to 2.8% of its shares through open market purchases. Share repurchase plans are often a sign that the company’s leadership believes its shares are undervalued.

NVIDIA Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Thursday, October 1st. Shareholders of record on Thursday, September 10th were given a $0.25 dividend. The ex-dividend date was Thursday, September 10th. This represents a $1.00 annualized dividend and a yield of 0.5%. NVIDIA’s payout ratio is 12.64%.

Wall Street Analyst Weigh In A number of equities research analysts have issued reports on the company. China Renaissance boosted their price target on NVIDIA from $319.00 to $330.00 and gave the company a “buy” rating in a research report on Monday, August 31st. HSBC raised their price objective on NVIDIA from $360.00 to $365.00 in a report on Thursday, August 27th. Rothschild & Co Redburn raised their price objective on NVIDIA from $300.00 to $325.00 in a report on Thursday, August 27th. Phillip Securities lifted their price objective on NVIDIA from $285.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, August 31st. Finally, Rosenblatt Securities reiterated a “buy” rating and set a $390.00 target price on shares of NVIDIA in a report on Tuesday, September 29th. Five investment analysts have rated the stock with a Strong Buy rating, forty-nine have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, NVIDIA currently has a consensus rating of “Buy” and a consensus target price of $321.89.

Read Our Latest Research Report on NVIDIA

NVIDIA Profile (Free Report)

NVIDIA Corporation is a technology company that designs accelerated computing platforms, graphics processing units (GPUs), central processing units (CPUs), networking products and related software. Its technologies are used in artificial intelligence, data centers, scientific and technical computing, gaming, professional visualization, automotive systems and robotics.

The company’s products include GeForce GPUs and gaming software, data center computing platforms, networking solutions, and enterprise software for AI development and deployment.

Featured Stories Five stocks we like better than NVIDIA Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding NVDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NVIDIA Corporation (NASDAQ:NVDA – Free Report).

Receive News & Ratings for NVIDIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NVIDIA and related companies with MarketBeat.com's FREE daily email newsletter.

The "Magnificent Seven" stocks have powered the S&P 500 higher over the past several years, thanks to their leadership in the technology space and, in many cases, their prominence in the high-potential area of artificial intelligence (AI). These companies operate across a range of specialty areas, from smartphones to social media, and each dominates its field -- and has established a strong track record of revenue growth over time.

You would expect such stocks to be particularly expensive after their gains in recent years. But that isn't the case. In fact, one stands out as a once-in-a-decade buying opportunity, as the cheapest of the "Magnificent Seven," and it's also close to its own valuation low. This AI stock has soared more than 900% over the past five years and is well-positioned for further gains as the AI story continues to unfold. Let's check out this surprisingly cheap stock to buy now, before the price goes up.

Image source: Getty Images.

Seven well-known tech giantsSo, first, let's take a quick look at the "Magnificent Seven." Most of us are probably familiar with these names, as they have built their reputations and businesses over time, and in most cases, their products are in the public eye. These companies are: Apple, Amazon, Alphabet, Meta Platforms, Microsoft, Nvidia (NVDA -1.43%), and Tesla.

Investors have rushed to get in on these stocks in recent years to bet on the AI story and technology in general. At times, valuations reached high levels, but today, many of them, in spite of the positive stock performance, are trading at reasonable prices. This is as earnings have also taken off.

And the best bargain of the bunch just so happens to be the biggest AI winner of all, at least so far, and that's Nvidia. The company trades for 23x forward earnings estimates, making it even cheaper than Meta, a stock that's been among the cheapest of the "Magnificent Seven" in recent years.

META PE Ratio (Forward) data by YCharts

Now, here's why I think such levels won't last and that this is a once-in-a-decade buying opportunity. We'll start by talking about the business Nvidia has built. The company is known for its graphics processing units (GPUs), the chips needed for essential AI tasks like the training of models. The GPU and Nvidia's related products and services have generated enormous earnings growth, with revenue and profit each climbing in the double and triple digits quarter after quarter. In the latest period, they reached $96 billion and $59 billion, respectively.

Why customers like the fastest GPUsCustomers rush to Nvidia because its GPUs are the fastest, and this is a major plus -- speed equals efficiency and over time may lower costs. Nvidia has expanded its repertoire as the AI boom has evolved, positioning itself to win in the upcoming phases of growth, and, with this in mind, it recently made a key move.

NVDA Nvidia$214.13-$3.10 (-1.43%)

NASDAQ · As of 4:00 PM ET 10/16/26

Nvidia has entered the stand-alone central processing unit (CPU) market as CPUs are seen as the key chips powering agentic AI. This involves AI handling real problems and taking multi-step actions, and it's viewed as a big growth driver in the coming years. Nvidia says the stand-alone CPU market is worth $200 billion, and the company aims to become a leader.

So, Nvidia's explosive growth in the early stages of the AI boom may not be the end of the story. The company could be heading for another big wave of growth as agentic AI use gathers momentum. Nvidia is in the process of rolling out its first CPUs and expects $20 billion in revenue from them this year alone. This offers us reason to be optimistic about what's ahead.

While Nvidia's explosive growth may keep its valuation somewhat in check, I still see today's level as exceptionally cheap -- and possibly a once-in-a-decade opportunity for growth investors looking for a long-term AI victory.

By You're currently following this author! Click to unsubscribe from email alerts.

Walmart is expecting up to an additional percentage point of inflation due to fuel costs in 2027, according to Deutsche Bank. David Paul Morris/Bloomberg via Getty Images Just when US shoppers might have thought they dodged the tariff jab, energy costs are coming in with the right hook.

Deutsche Bank says Walmart executives are now expecting the added cost of higher diesel prices to wipe out their total expected benefit from tariff refunds and push prices back up, according to a Thursday analyst note following a meeting with Walmart CFO John David Rainey.

"Elevated diesel is pressuring WMT directly through transportation costs and indirectly as suppliers pass through higher costs, including on petroleum-linked products," the analysts wrote. "Elevated diesel costs are beginning to flow through to consumer prices"

The company is now expecting an additional half to one percentage point of inflation in 2027, the note said. At that rate, additional fuel costs this year and next year will completely erase Walmart's $2.9 billion tariff refund.

Walmart said in August that it had been putting the bulk of that tariff refund money toward lower prices for shoppers.

"Like other retailers, we are not immune to sustained increases in fuel and transportation costs, but we work to minimize their impact," a spokesperson told Business Insider.

The spokesperson also said that many of Walmart's current discounts and holiday deals are time-bound, after which some prices may return to regular levels.

"That should not be characterized as a broad-based price increase," the spokesperson said.

Beyond Walmart, which runs one of the most efficient supply chains in all of retail, the energy impact could be even more pronounced.

The Deutsche Bank analysts noted that competing retailers are also hiking prices in similar categories, leaving Walmart with the relative low-price advantage. The bank also upgraded its rating of Walmart's stock.

Read next

Business Insider tells the innovative stories you want to know

Business Insider tells the innovative stories you want to know

Business Insider tells the innovative stories you want to know

Business Insider tells the innovative stories you want to know

Dominick Reuter You're currently following this author! Click to unsubscribe from email alerts.

Dominick Reuter is a senior retail reporter for Business Insider, primarily covering Walmart, Target, Costco, and other big box retailers. His stories tend to focus on issues and trends that affect employees and customers, such as affordability challenges and the growing race to provide ultra-fast delivery services on e-commerce orders.Prior to joining BI in 2019, Dominick worked for more than a decade as an independent photojournalist covering a wide range of stories for global wire services and newspapers, including Reuters, the Wall Street Journal, and Agence France-Presse.Dominick studied photojournalism at Boston University and later earned a Masters in business and economics journalism from Columbia University.If you're an employee or customer with a story to share, please contact me via email or text/call/Signal at 646-768-4750.

Walmart

Banque Pictet & Cie SA boosted its stake in shares of PepsiCo, Inc. (NASDAQ:PEP – Free Report) by 14.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 174,844 shares of the company’s stock after buying an additional 21,663 shares during the quarter. Banque Pictet & Cie SA’s holdings in PepsiCo were worth $22,156,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PEP. Rise Advisors LLC grew its holdings in PepsiCo by 17.1% during the 3rd quarter. Rise Advisors LLC now owns 1,852 shares of the company’s stock valued at $235,000 after buying an additional 271 shares in the last quarter. James T. Borello RIA purchased a new stake in shares of PepsiCo in the third quarter worth about $131,000. V Square Quantitative Management LLC lifted its holdings in shares of PepsiCo by 4.1% in the third quarter. V Square Quantitative Management LLC now owns 31,761 shares of the company’s stock worth $4,025,000 after buying an additional 1,265 shares in the last quarter. YANKCOM Partnership boosted its position in shares of PepsiCo by 9.2% in the third quarter. YANKCOM Partnership now owns 11,260 shares of the company’s stock valued at $1,427,000 after acquiring an additional 945 shares during the period. Finally, Financial & Tax Architects LLC grew its stake in PepsiCo by 7.4% during the third quarter. Financial & Tax Architects LLC now owns 52,098 shares of the company’s stock valued at $6,602,000 after acquiring an additional 3,589 shares in the last quarter. Institutional investors own 73.07% of the company’s stock.

Insider Buying and Selling at PepsiCo In other news, Director Robert Pohlad acquired 184,646 shares of PepsiCo stock in a transaction that occurred on Wednesday, October 14th. The shares were bought at an average cost of $128.28 per share, with a total value of $23,686,388.88. Following the transaction, the director directly owned 433,009 shares of the company’s stock, valued at $55,546,394.52. This trade represents a 74.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, EVP David Flavell sold 2,900 shares of the firm’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $139.54, for a total transaction of $404,666.00. Following the completion of the sale, the executive vice president directly owned 74,825 shares of the company’s stock, valued at approximately $10,441,080.50. The trade was a 3.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.12% of the company’s stock.

Wall Street Analysts Forecast Growth PEP has been the topic of several analyst reports. JPMorgan Chase & Co. decreased their price objective on PepsiCo from $138.00 to $137.00 and set a “neutral” rating on the stock in a report on Friday, October 9th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $132.00 target price on shares of PepsiCo in a report on Friday, October 9th. Weiss Ratings lowered PepsiCo from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday, September 24th. UBS Group decreased their price target on PepsiCo from $159.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, October 2nd. Finally, Piper Sandler lowered their price objective on PepsiCo from $176.00 to $140.00 and set an “overweight” rating for the company in a research report on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $145.50. Read Our Latest Stock Report on PEP

PepsiCo Stock Performance Shares of NASDAQ PEP opened at $131.49 on Friday. The firm’s 50-day moving average price is $134.44 and its 200-day moving average price is $142.25. The company has a quick ratio of 0.76, a current ratio of 0.94 and a debt-to-equity ratio of 1.90. The company has a market cap of $179.19 billion, a PE ratio of 15.27, a PEG ratio of 3.82 and a beta of 0.35. PepsiCo, Inc. has a 52-week low of $123.47 and a 52-week high of $171.48.

PepsiCo (NASDAQ:PEP – Get Free Report) last issued its quarterly earnings results on Wednesday, October 7th. The company reported $2.34 EPS for the quarter, topping analysts’ consensus estimates of $2.29 by $0.05. The business had revenue of $25.27 billion during the quarter, compared to analysts’ expectations of $24.95 billion. PepsiCo had a return on equity of 53.08% and a net margin of 11.09%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.29 earnings per share. As a group, analysts anticipate that PepsiCo, Inc. will post 8.41 EPS for the current year.

Key Headlines Impacting PepsiCo Here are the key news stories impacting PepsiCo this week:

Positive Sentiment: Director Robert Pohlad bought 184,646 shares for approximately $23.7 million, increasing his direct ownership by 74.35%. The purchase may signal confidence that PepsiCo’s depressed valuation does not reflect its long-term prospects. SEC insider transaction filing Positive Sentiment: Bank of America maintained a Hold rating but raised its price target to $145, suggesting balanced risk-reward and potential upside from current levels. The firm cited strength at Taco Bell as partially offsetting the KFC loss. Bank of America rating update Neutral Sentiment: PepsiCo announced a €500 million offering of 3.750% senior notes. The proceeds strengthen funding flexibility, although the transaction adds to the company’s already elevated debt burden. PepsiCo euro-denominated senior notes announcement Neutral Sentiment: PepsiCo, its foundation and Feed the Children reported distributing 2 million meals through a school-based hunger-relief program. The announcement supports corporate reputation but is unlikely to materially affect earnings. PepsiCo hunger-relief program announcement Negative Sentiment: KFC will replace Pepsi beverages with Coca-Cola products at U.S. restaurants beginning in January 2027, with a full rollout expected by spring. Although KFC represents a limited portion of PepsiCo’s sales, investors view the loss as a setback for its U.S. food-service business and brand presence. Reuters report on KFC switching beverage suppliers Negative Sentiment: In India, PepsiCo warned that its Sting and Adrenaline Rush energy drinks could run out within two months after a court declined to suspend restrictions on “energy drink” labeling. The dispute could cause supply disruptions and allow competitors such as Red Bull to gain share. PepsiCo India energy-drink supply report About PepsiCo (Free Report)

PepsiCo, Inc (NASDAQ:PEP) is a global food and beverage company that develops, manufactures, markets and distributes a broad portfolio of snacks, drinks and convenient foods. Its beverage brands include Pepsi, Mountain Dew, Gatorade, 7UP in select markets, and bubly, while its food and snack brands include Lay’s, Doritos, Cheetos, Tostitos, Fritos, Quaker and Ruffles.

The company’s operations include beverage production and distribution, snack foods, convenient meals and nutrition-oriented products.

See Also Five stocks we like better than PepsiCo Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding PEP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PepsiCo, Inc. (NASDAQ:PEP – Free Report).

Receive News & Ratings for PepsiCo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepsiCo and related companies with MarketBeat.com's FREE daily email newsletter.

Annex Advisory Services LLC boosted its position in shares of Deere & Company (NYSE:DE – Free Report) by 1.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,109 shares of the industrial products company’s stock after buying an additional 890 shares during the period. Annex Advisory Services LLC’s holdings in Deere & Company were worth $39,694,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Deere & Company in the 2nd quarter valued at about $11,763,504,000. Wellington Management Group LLP increased its stake in Deere & Company by 84.3% during the second quarter. Wellington Management Group LLP now owns 3,088,628 shares of the industrial products company’s stock worth $1,959,209,000 after acquiring an additional 1,412,694 shares during the last quarter. Bank of America Corp DE bought a new stake in Deere & Company during the second quarter worth approximately $1,685,093,000. Bank of New York Mellon Corp bought a new stake in shares of Deere & Company in the 2nd quarter valued at approximately $1,259,279,000. Finally, Legal & General Group Plc bought a new stake in shares of Deere & Company in the 2nd quarter valued at approximately $957,456,000. Hedge funds and other institutional investors own 68.58% of the company’s stock.

Deere & Company Price Performance Shares of DE stock opened at $641.46 on Friday. Deere & Company has a twelve month low of $454.50 and a twelve month high of $721.22. The company has a current ratio of 2.10, a quick ratio of 1.89 and a debt-to-equity ratio of 1.45. The stock has a fifty day simple moving average of $658.05 and a two-hundred day simple moving average of $611.83. The stock has a market capitalization of $172.95 billion, a price-to-earnings ratio of 36.15, a P/E/G ratio of 2.38 and a beta of 0.86.

Deere & Company (NYSE:DE – Get Free Report) last announced its quarterly earnings results on Thursday, August 20th. The industrial products company reported $5.10 EPS for the quarter, beating the consensus estimate of $4.69 by $0.41. Deere & Company had a return on equity of 18.10% and a net margin of 10.16%. The firm had revenue of $12.61 billion for the quarter, compared to analyst estimates of $10.81 billion. During the same quarter last year, the firm posted $4.75 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, analysts predict that Deere & Company will post 18.11 EPS for the current fiscal year. Deere & Company Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Monday, November 9th. Stockholders of record on Wednesday, September 30th will be issued a $1.62 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $6.48 annualized dividend and a dividend yield of 1.0%. Deere & Company’s payout ratio is currently 36.00%.

Analysts Set New Price Targets Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Deere & Company from $585.00 to $625.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Weiss Ratings upgraded shares of Deere & Company from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, September 21st. Wall Street Zen lowered shares of Deere & Company from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd. DA Davidson raised their price objective on shares of Deere & Company from $685.00 to $760.00 and gave the stock a “buy” rating in a research note on Monday, August 24th. Finally, Seaport Research Partners set a $570.00 target price on Deere & Company in a research report on Friday, August 14th. Seventeen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $688.10.

View Our Latest Stock Analysis on DE

Deere & Company Profile (Free Report)

Deere & Company, commonly known as John Deere, is a global manufacturer of agricultural, construction, forestry and turf-care equipment. The company’s products include tractors, combines, planters, sprayers, harvesting equipment, earthmoving machinery, forestry equipment, commercial and residential lawn-care products, and related technology solutions.

Deere operates through businesses serving production and precision agriculture, small agriculture and turf, and construction and forestry markets.

Further Reading Five stocks we like better than Deere & Company Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding DE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deere & Company (NYSE:DE – Free Report).

Receive News & Ratings for Deere & Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deere & Company and related companies with MarketBeat.com's FREE daily email newsletter.

Plug Power (PLUG -7.07%), a developer of hydrogen charging technologies, went public in 1999 at a reverse-split-adjusted price of $150. It reached a record high of $1,498 at the peak of the dot-com bubble in early 2020, but now trades at roughly $1 per share. Could investing $1,000 in this beaten-down stock generate life-changing gains for daring investors?

Image source: Getty Images.

What happened to Plug Power? Plug Power originally planned to build hydrogen charging systems for homes. But after those ambitious plans fizzled out, it pivoted toward hydrogen fuel cells, charging systems, electrolyzers, and storage systems. It's already deployed 76,000 fuel cell systems, but it's heavily dependent on Amazon and Walmart, both of which use its fuel cells and charging systems in their hydrogen-powered forklifts. However, most of Plug's recent growth has been driven by its sales of electrolyzers for new decarbonization projects.

$1.38-$0.11 (-7.07%)

NASDAQ · As of 4:00 PM ET 10/16/26

Plug struggled with lumpy revenue growth over the past few years as the macro headwinds disrupted hydrogen charging projects. But from 2025 to 2028, analysts expect its revenue to grow at an 18% CAGR as it narrows its net losses. That's an impressive growth trajectory for a stock that trades at less than two times next year's sales.

Plug Power could command a higher valuation and deliver multibagger gains over the next decade if it diversifies its business beyond Amazon and Walmart and successfully executes its "Project Quantum Leap" cost-cutting initiatives. However, it's still a speculative stock that could be easily delisted if it can't prove its business model is sustainable.

Leo Sun has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Walmart. The Motley Fool has a disclosure policy.

First Citizens Bank & Trust Co. reduced its position in Unum Group (NYSE:UNM – Free Report) by 55.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,198 shares of the financial services provider’s stock after selling 11,352 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Unum Group were worth $807,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its position in shares of Unum Group by 7.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,084,382 shares of the financial services provider’s stock worth $298,287,000 after buying an additional 292,670 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of Unum Group during the 2nd quarter valued at approximately $84,097,000. Donald Smith & CO. Inc. bought a new stake in shares of Unum Group during the 2nd quarter valued at approximately $58,064,000. Bank of America Corp DE bought a new stake in shares of Unum Group during the 2nd quarter valued at approximately $55,273,000. Finally, Quantinno Capital Management LP increased its position in Unum Group by 14.6% during the 1st quarter. Quantinno Capital Management LP now owns 754,335 shares of the financial services provider’s stock worth $55,089,000 after purchasing an additional 96,123 shares in the last quarter. 86.57% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades UNM has been the subject of several research reports. JPMorgan Chase & Co. dropped their price objective on shares of Unum Group from $101.00 to $98.00 and set a “neutral” rating for the company in a research note on Monday, August 3rd. Wells Fargo & Company upped their price target on shares of Unum Group from $100.00 to $102.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Weiss Ratings upgraded Unum Group from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, July 28th. Atlantic Securities set a $88.00 price target on Unum Group in a research note on Wednesday, July 15th. Finally, Jefferies Financial Group raised their price objective on Unum Group from $117.00 to $123.00 and gave the company a “buy” rating in a report on Friday, July 10th. Eight research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Unum Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.42.

Get Our Latest Analysis on Unum Group Unum Group Stock Down 0.1% Shares of NYSE UNM opened at $92.28 on Friday. The company has a 50 day simple moving average of $92.10 and a 200 day simple moving average of $87.12. The firm has a market cap of $14.61 billion, a PE ratio of 11.12, a price-to-earnings-growth ratio of 0.90 and a beta of 0.25. Unum Group has a 1 year low of $69.02 and a 1 year high of $96.77. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.34 and a quick ratio of 0.34.

Unum Group (NYSE:UNM – Get Free Report) last posted its earnings results on Tuesday, July 28th. The financial services provider reported $2.16 EPS for the quarter, hitting the consensus estimate of $2.16. Unum Group had a net margin of 5.26% and a return on equity of 12.60%. The business had revenue of $3.39 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same period last year, the company earned $1.92 EPS. The firm’s revenue was up .3% compared to the same quarter last year. Unum Group has set its FY 2026 guidance at 8.600-8.900 EPS. On average, research analysts forecast that Unum Group will post 8.64 EPS for the current year.

Unum Group Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Friday, November 20th. Stockholders of record on Friday, October 30th will be issued a dividend of $0.5050 per share. This represents a $2.02 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, October 30th. Unum Group’s payout ratio is 47.09%.

Unum Group announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, August 26th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the financial services provider to buy up to 7% of its shares through open market purchases. Share repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Insider Transactions at Unum Group In related news, EVP Lisa G. Iglesias sold 4,000 shares of the stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $94.44, for a total value of $377,760.00. Following the completion of the sale, the executive vice president directly owned 25,453 shares in the company, valued at $2,403,781.32. This represents a 13.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Walter Lynn Rice, Jr. sold 2,188 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $94.31, for a total value of $206,350.28. Following the transaction, the chief accounting officer directly owned 8,154 shares of the company’s stock, valued at approximately $769,003.74. This represents a 21.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 10,488 shares of company stock worth $988,396. Company insiders own 1.00% of the company’s stock.

Unum Group Company Profile (Free Report)

Unum Group is an insurance company that provides employee benefits and related financial protection products to individuals, employers and their workforces. Its offerings include disability insurance, group and individual life insurance, accidental death and dismemberment coverage, long-term care insurance, and supplemental health benefits.

The company serves employers through workplace benefits programs, including absence-management and leave-administration services. Through its Colonial Life business, Unum also offers voluntary benefits such as accident, critical illness, hospital indemnity and dental insurance, which employees may obtain through the workplace.

Unum Group traces its history to 1848, when Union Mutual Life Insurance Company was established in Maine.

See Also Five stocks we like better than Unum Group Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?

Receive News & Ratings for Unum Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Group and related companies with MarketBeat.com's FREE daily email newsletter.

Banque Pictet & Cie SA trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 65.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 373,583 shares of the medical equipment provider’s stock after selling 694,882 shares during the quarter. Banque Pictet & Cie SA’s holdings in Boston Scientific were worth $16,307,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of BSX. Cyndeo Wealth Partners LLC grew its position in Boston Scientific by 4.3% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 62,339 shares of the medical equipment provider’s stock worth $2,721,000 after purchasing an additional 2,549 shares during the last quarter. Aspiriant LLC acquired a new position in Boston Scientific in the 3rd quarter valued at about $338,000. Goelzer Investment Management Inc. raised its stake in Boston Scientific by 287.8% during the 3rd quarter. Goelzer Investment Management Inc. now owns 49,215 shares of the medical equipment provider’s stock valued at $2,148,000 after acquiring an additional 36,524 shares during the last quarter. Activest Wealth Management raised its stake in Boston Scientific by 202.6% during the 3rd quarter. Activest Wealth Management now owns 1,831 shares of the medical equipment provider’s stock valued at $87,000 after acquiring an additional 1,226 shares during the last quarter. Finally, V Square Quantitative Management LLC lifted its position in Boston Scientific by 26.4% during the 3rd quarter. V Square Quantitative Management LLC now owns 14,164 shares of the medical equipment provider’s stock worth $618,000 after acquiring an additional 2,956 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets BSX has been the subject of a number of recent analyst reports. Royal Bank Of Canada reduced their price objective on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, July 30th. Citigroup dropped their target price on Boston Scientific from $50.00 to $48.00 and set a “neutral” rating on the stock in a research report on Monday, October 5th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Wells Fargo & Company reduced their price target on Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating for the company in a report on Wednesday, September 23rd. Finally, Truist Financial decreased their price target on Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average price target of $68.23.

Read Our Latest Stock Report on BSX Insider Buying and Selling In related news, CEO Michael F. Mahoney bought 186,240 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 194,522 shares of company stock valued at $9,385,210 in the last quarter. Company insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 0.5% Shares of NYSE BSX opened at $44.34 on Friday. Boston Scientific Corporation has a 52-week low of $41.38 and a 52-week high of $105.65. The firm has a fifty day moving average of $46.06 and a 200-day moving average of $49.76. The stock has a market capitalization of $64.26 billion, a PE ratio of 13.75, a P/E/G ratio of 1.07 and a beta of 0.58. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts anticipate that Boston Scientific Corporation will post 3.24 EPS for the current year.

Boston Scientific Company Profile (Free Report)

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

Read More Five stocks we like better than Boston Scientific Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Assenagon Asset Management S.A. grew its holdings in shares of MKS Inc. (NASDAQ:MKSI – Free Report) by 1,742.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 442,273 shares of the scientific and technical instruments company’s stock after buying an additional 418,264 shares during the period. Assenagon Asset Management S.A. owned 0.65% of MKS worth $117,362,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Loftus Peak Pty Ltd boosted its position in shares of MKS by 21.4% in the 3rd quarter. Loftus Peak Pty Ltd now owns 57,593 shares of the scientific and technical instruments company’s stock worth $15,283,000 after purchasing an additional 10,157 shares in the last quarter. First Citizens Bank & Trust Co. purchased a new stake in shares of MKS in the third quarter worth $575,000. NorthCrest Asset Manangement LLC increased its holdings in shares of MKS by 19.5% during the third quarter. NorthCrest Asset Manangement LLC now owns 1,262 shares of the scientific and technical instruments company’s stock valued at $329,000 after acquiring an additional 206 shares in the last quarter. Wedmont Private Capital increased its holdings in shares of MKS by 2.3% during the third quarter. Wedmont Private Capital now owns 4,193 shares of the scientific and technical instruments company’s stock valued at $1,092,000 after acquiring an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of MKS by 13.5% during the third quarter. GAMMA Investing LLC now owns 3,667 shares of the scientific and technical instruments company’s stock valued at $973,000 after acquiring an additional 436 shares in the last quarter. 99.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades Several brokerages recently commented on MKSI. Deutsche Bank Aktiengesellschaft set a $360.00 price objective on shares of MKS in a research report on Friday, July 31st. Wall Street Zen raised shares of MKS from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Bank of America upped their target price on shares of MKS from $380.00 to $500.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. Needham & Company LLC increased their price target on shares of MKS from $360.00 to $390.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Citigroup increased their price target on shares of MKS from $425.00 to $430.00 and gave the company a “buy” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $375.93.

Get Our Latest Report on MKS MKS Trading Down 6.0% MKSI opened at $214.83 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.72 and a debt-to-equity ratio of 0.85. MKS Inc. has a 12 month low of $130.72 and a 12 month high of $447.62. The firm has a market cap of $14.53 billion, a P/E ratio of 34.26, a P/E/G ratio of 0.48 and a beta of 2.03. The stock has a 50-day moving average of $265.44 and a 200 day moving average of $299.66.

MKS (NASDAQ:MKSI – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The scientific and technical instruments company reported $3.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.91 by $0.39. The company had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $1.20 billion. MKS had a return on equity of 24.72% and a net margin of 10.15%. MKS’s revenue was up 28.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.77 EPS. MKS has set its Q3 2026 guidance at 3.270-3.890 EPS. As a group, research analysts forecast that MKS Inc. will post 13.13 EPS for the current year.

MKS Announces Dividend The business also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Tuesday, August 25th were given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 25th. MKS’s dividend payout ratio (DPR) is 15.95%.

Insider Buying and Selling at MKS In related news, Director Elizabeth Mora sold 300 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $250.96, for a total transaction of $75,288.00. Following the transaction, the director directly owned 18,845 shares in the company, valued at $4,729,341.20. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Williams sold 457 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $288.31, for a total value of $131,757.67. Following the sale, the executive vice president owned 4,098 shares in the company, valued at $1,181,494.38. The trade was a 10.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 10,757 shares of company stock valued at $3,227,146. 0.57% of the stock is currently owned by insiders.

MKS Company Profile (Free Report)

MKS Instruments, Inc develops technologies used to measure, control and analyze the processes involved in manufacturing semiconductors, electronics, specialty materials and other industrial products. The company serves original equipment manufacturers and production facilities worldwide, with solutions spanning vacuum control, pressure measurement, gas and fluid delivery, process monitoring and control.

Its product portfolio includes vacuum gauges and valves, mass flow controllers, gas and vapor delivery systems, pressure controllers, plasma-generation and power-delivery systems, analytical instruments, lasers and photonics equipment.

Featured Articles Five stocks we like better than MKS Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding MKSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MKS Inc. (NASDAQ:MKSI – Free Report).

Receive News & Ratings for MKS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MKS and related companies with MarketBeat.com's FREE daily email newsletter.

Not all high-yield dividend stocks are created equal. Some are genuine income compounders, while others are traps. And the current environment, with interest rates on the rise, makes it more difficult to differentiate the good from the bad.

AbbVie (ABBV +0.71%) is by no means a high-yield trap. This pharma stock is well-positioned to succeed in any rate cycle.

Image source: Getty Images.

The exact opposite of a high-yield trap What makes a stock a high-yield trap? Different investors can have different criteria, but there's one tell-tale sign. A stock with a high dividend yield but a payout ratio consistently above its free cash flow is almost always a trap. If a company doesn't generate sufficient free cash flow, it will be forced to cut its dividend sooner or later.

Rising interest rates make it especially difficult for companies with balance sheets loaded to the gills with floating-rate debt. They frequently must shift funds from the dividend program to cover their higher interest expenses.

Similarly, a company with a business model whose revenue is highly sensitive to consumer spending can experience problems when rates increase. When consumers have to spend more of their money on car and home loans and credit card debt, they have less money to buy these companies' products.

AbbVie doesn't have issues on any of these fronts. The drugmaker generates more than enough free cash flow to cover its quarterly dividend payment of $1.73 per share. While AbbVie's debt totals $70.8 billion, much of it is in fixed-rate senior notes that aren't sensitive to interest rate fluctuations. Patients don't quit taking AbbVie's medications because interest rates go up, either.

ABBV AbbVie$285.42+$2.02 (+0.71%)

NYSE · As of 4:00 PM ET 10/16/26

The numbers add up for AbbVie Importantly, AbbVie has increased its dividend for 54 consecutive years (including the period when it was part of Abbott Laboratories (ABT +0.20%)). This achievement qualifies the company to be part of the Dividend Kings, a group of stocks that have increased their dividends for at least 50 consecutive years.

As you might imagine, Dividend Kings are loath to break their dividend-hike streaks and lose their status in the elite group. Both Abbott and AbbVie have ensured their dividends keep flowing and growing regardless of what the Federal Reserve does with rates.

AbbVie shouldn't have much trouble holding onto its Dividend King membership for two key reasons: Skyrizi and Rinvoq. These two autoimmune disease drugs together raked in over $7.5 billion in the second quarter of 2026 alone. That's more than the $6.1 billion the company paid in dividends during the quarter.

Another important number to know is 90. That's roughly how many programs the company has in clinical development. Around 60 of them are in mid- or late-stage clinical studies. This robust pipeline should help ensure that AbbVie continues to generate plenty of revenue in the future to grow its dividend.

A Dividend King to own for the long run To be sure, AbbVie's dividend yield of 2.5% isn't nearly as high as it's been in the past. However, that isn't a poor reflection on the company's ability to pay dividends. Instead, it's a testament to how great AbbVie's stock has performed in recent years. Its share price has risen so much that the solid dividend growth hasn't kept pace, causing this yield to slide.

Like all biotech and pharmaceutical companies, AbbVie faces the risk of pipeline setbacks. The good news, though, is that the company has enough therapies in development to remain successful even if some don't fulfill their potential.

In a market where investors can easily get stuck with high-yield traps, AbbVie offers a solution. It's an ideal Dividend King to own for the long run.

Shares of ad tech company The Trade Desk (TTD -6.86%) trade near $12 as I write, down about 91% from their December 2024 record closing price of $139.51. And shares have kept sliding this year, down about 68% since the end of 2025.

The company's now worth about $5.8 billion, and the stock costs about 14 times its earnings for the last 12 months. For a business whose revenue rose 18% year over year in 2025, that looks cheap. But management now expects revenue to shrink.

Where could the stock realistically be in a bit over three years?

My estimate is around $16 a share by the end of 2029, about 31% above today's price, or a gain of about 9% a year. I think it's a fair middle case. But it hinges on something the company hasn't forecast yet: a return to growth.

Image source: Getty Images.

Shrinking sales, fewer sharesThe Trade Desk is a tech company that runs a demand-side platform (software advertisers use to buy digital ads automatically), and as recently as last year the business looked healthy. Full-year 2025 revenue hit around $2.9 billion, and net income climbed about 13% to $443 million -- a net margin of about 15%.

Growth has since slowed sharply. Second-quarter 2026 revenue rose just 3% year over year to $715 million. Net income dropped around 29% to $64 million, cutting the net margin to 9% from 13% in the year-ago quarter. And management's guidance calls for third-quarter revenue of at least $650 million, which would be a decline of about 12% from the same period in 2025.

Still, one number keeps moving in shareholders' favor. Mainly because of buybacks, the company's diluted share count dropped from around 507 million in late 2024 to 483 million a year later, then to 470 million by this year's second quarter. The Trade Desk repurchased about 10 million shares for about $233 million in the first half of 2026 alone, and it still had about $1.5 billion in cash and short-term investments and no debt at the end of June.

So per-share earnings can arguably rise faster than profits, even if the business recovers slowly.

What would it take to hit $16?Say revenue rebounds to 2025's level of about $2.9 billion by 2027 and then rises about 6% a year. This gets The Trade Desk to about $3.3 billion of revenue in 2029, growth at about a third of the rate it managed in 2025.

If the net margin also returns to the 15% the business had in 2025, net income could be near $490 million in 2029.

Assume buybacks cut the diluted share count to about 450 million, a slower rate of decline than the past 18 months. That works out to about $1.09 of earnings per share.

At 15 times earnings (near the price-to-earnings ratio the stock trades at now), shares would be worth around $16.

Notably, I'm not assuming a higher valuation multiple, just that the company stops shrinking and earns its 2025 net margin again.

$12.23-$0.90 (-6.86%)

NASDAQ · As of 4:00 PM ET 10/16/26

A lot could go wrongThe biggest risk is that revenue doesn't rebound on that schedule. If sales settle around $2.8 billion and the net margin stalls at about 10%, earnings per share could be about $0.61 on 460 million shares. At 12 times earnings, the stock would be worth around $7, or about 40% below its current price.

The share count assumption has its own risk. On Monday, Oct. 19, shareholders vote on a proposal to reprice stock options for up to around 15.6 million shares, or about 3% of the outstanding shares. Exercise prices for these options go up to $122.59, and if the proposal passes, any above that day's closing price would be cut to the close. Options priced near the stock might increase dilution if shares recover, which is the scenario my forecast assumes.

In the end, a gain of around 9% a year would be a decent result from here. But it hinges on a recovery The Trade Desk hasn't guided to, and my bear case drops more than my base case climbs. This prediction doesn't change the take I spelled out last month, when I explained why I'm still not buying the stock.

Until management's revenue forecast points up again, I'd rather not pay even 14 times earnings for the shares. Sure, three years is a long time, and my estimate could miss in either direction.

Walt Disney's (DIS -0.08%) place is in the living room. Its popular cable channels helped it establish a dominant position in the media and entertainment industry. But this part of the business faces secular decline, as U.S. households have been cutting the cord. The linear networks aren't as lucrative as they once were.

The company has transitioned successfully this decade in the streaming age. It's been a costly evolution, though. But Disney+, Hulu, and the direct-to-consumer (DTC) ESPN platform give Disney a comprehensive content offering that caters to everyone in the family.

While changes have happened on the TV screen, the experiences segment continues to drive the lion's share of financial results. And the business is investing aggressively here.

Shareholders have witnessed multiple CEO changes, from Bob Chapek to Bob Iger to Josh D'Amaro. And the consumer discretionary stock has disappointed amid all of this turbulence. It currently trades 46% off its peak (as of Oct. 14). And it's down 4% in 2026, lagging the broader market.

There's one stat, however, that makes the House of Mouse hard to ignore in October.

Image source: The Motley Fool.

The valuation represents a discount to the market Disney shares trade at a forward price-to-earnings ratio of 13.8 right now. That's significantly cheaper than the S&P 500's 19.6 multiple. It looks like a compelling bargain opportunity. That point carries extra weight when the market is near record territory. And given that it's been four years since this raging bull market started, investors might find it challenging to identify reasonably valued stocks.

As noted earlier, Disney hasn't been running a simple and easy-to-follow business. It seems that there are a lot of moving parts. And the market could be punishing the stock because of it.

The legacy cable networks continue to be a financial drag. From fiscal 2022 to fiscal 2025 (last available data), operating income fell 65%. That's not surprising because, according to eMarketer, the number of cable-TV households in the U.S. will decline again in 2026 to 54 million. That's down from 105 million households in 2010. Consumers have increasingly moved their attention to streaming entertainment, which has hurt legacy media players.

And this is a capital-intensive business. In addition to expanding its experiences division, Disney must constantly invest in content that seems to get more expensive every year. This is particularly true with valuable sports rights. Big tech enterprises have entered the arena, which can result in costly bidding wars.

Competition for eyeballs is also intense these days. And it's a crowded race to capture consumer discretionary spending. Moreover, the investment community might simply be chasing what has been the hottest trade, which is owning artificial intelligence stocks.

$110.59-$0.09 (-0.08%)

NYSE · As of 4:00 PM ET 10/16/26

Take a five-year view Knowing the negative factors, I still believe the valuation makes Disney shares too hard to ignore this month. For less than 14 times forward earnings, investors can own a stake in a high-quality company.

It all starts with something that no rival can copy, which is Disney's intellectual property (IP). Decades of characters, franchises, and stories can't be rebuilt with any amount of capital. This supports the company's economic moat.

The entertainment DTC operations, including Disney+ and Hulu (excluding live TV), have turned the corner on profitability. Operating income soared more than 100% year over year in Q3 (ended June 27) to $712 million. In fiscal 2022, it posted a sizable operating loss of $4 billion (including ESPN+). This is an emerging bottom-line tailwind.

Then there's the experience segment. The main drivers here are the theme parks and cruises, both of which are expanding as part of a 10-year, $60 billion capital expenditure cycle announced three years ago. The segment's Q3 operating income of $3 billion, accounting for 54% of the company's total, demonstrates how lucrative it is for Disney to bring its IP to life.

Patient investors with a five-year horizon have plenty to like here.

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs
Latest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitis
New data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presented

, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain. Together, the data reflect the breadth of AbbVie's research across IBD, including established therapies studied over longer treatment periods and in real-world clinical practice.

"Crohn's disease and ulcerative colitis are chronic, lifelong conditions, and understanding how patients respond to treatment over time and in everyday clinical practice is critical," said Sofie Berg, Pharm.D., Ph.D., therapeutic area head, immunology, international medical affairs, AbbVie. "The data presented at UEGW 2026 build on our growing body of evidence that can help clinicians move toward favorable long-term outcomes for people living with IBD."

Key data to be presented include:

Long-term data in moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) – Open-label extension and post-hoc analyses add to the evidence base for clinical and endoscopic outcomes with risankizumab and upadacitinib

Risankizumab in UC: COMMAND showed sustained clinical and endoscopic outcomes up to three years of maintenance treatment. As-observed clinical remissiona rates of 54.0%–73.1% and endoscopic remissionb rates of 38.8%–53.5% were achieved at week 96 with 180mg across advanced therapy-naïve and advanced therapy-experienced patients.
Upadacitinib in CD: U-ENDURE as-observed analyses showed that clinical and endoscopic outcomes were maintained through approximately four years of treatment. At Week 144, clinical remissionc was achieved by 78.9% of patients receiving 15 mg and 86.6% receiving 30 mg. Endoscopic remissiond was achieved by 47.1% and 64.2% of patients, respectively.

Upadacitinib in the Real World: New Insights from Clinical Practice

Interim results from the real-world UPlift study showed that 70.2% of evaluable patients (N=497) with moderate to severe Crohn's disease achieved clinical responsee with upadacitinib within 12 weeks, with a median time to first response of 13 days.
A real-world claims analysis of patients (N=514) with UC or CD showed that patients who switched from a Tumor Necrosis Factor inhibitor (TNFi) to upadacitinib had lower rates of IBD-related hospitalizations (9.5% vs 16.3%) or surgery (6.9% vs 10.6%) over 12 months compared with patients who cycled to another TNFi.

Additional Findings on Risankizumab Subcutaneous Induction in CD

Data presented at UEGW will further expand on findings from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab induction and maintenance in CD. Following the first presentation of AFFIRM results at the 2026 American College of Gastroenterology Annual Scientific Meeting, the UEGW presentations will provide additional analyses examining outcomes by prior advanced therapy exposure and further characterizing clinical and endoscopic outcomes among patients who responded to subcutaneous risankizumab induction and continued treatment.

aDefined as stool frequency (SF) score ≤ 1, and not greater than baseline, rectal bleeding score = 0, and endoscopic subscore ≤ 1 without evidence of friability.
bDefined as endoscopic subscore = 0.
cDefined as average daily very soft or liquid SF ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than induction baseline.
dDefined as Simplified Endoscopic Score for Patients with Crohn's Disease ≤ 4 and at least a 2-point reduction from baseline and no subscore > 1 in any individual variable, as scored by a central reviewer.
eDefined as the first day with ≥30% decrease in daily very soft or liquid SF and/or ≥30% decrease in daily AP score and both not worse than baseline AND a prospective 7-day average daily CR-PRO starting on the first day of daily CR-PRO; prospective 7-day average daily CR-PRO was defined as ≥30% decrease in average daily very soft or liquid SF and/or ≥30% decrease in average daily AP score and both not worse than baseline. Only patients with either baseline SF or AP >0 and both non-missing with at least one postbaseline assessment of CR-PRO2 are included.

The 2026 UEGW Congress program is available here. Select abstracts and oral presentations from AbbVie include:

Presentation Title

Session Details

Efficacy of Risankizumab by Crohn's Disease
Location: Results From 144 Weeks of the
FORTIFY Open-Label Extension Study

Oral

Monday, 19 October

16:00 – 17:00

OP165: Teaching an old dog new tricks:
New implementations of current IBD drug

Efficacy and Safety of Risankizumab
Subcutaneous Induction in Patients With
Moderately to Severely Active Crohn's Disease:
Week 12 Results From the Phase 3 AFFIRM Study

Oral

Monday, 19 October

16:00 – 17:00

OP166: Teaching an old dog new tricks:
New implementations of current IBD drug

Efficacy and Safety of Subcutaneous
Risankizumab Maintenance Therapy Among
Patients With Moderately to Severely Active
Crohn's Disease Who Responded to
Subcutaneous Risankizumab Induction Therapy:
24-Week Results From the AFFIRM Trial

Moderated poster

Monday, 19 October

16:00 – 17:00

MP0087: The IBD exposome: Diet,
environment, and sustainability

Sustained Clinical and Endoscopic Improvements With
up to 3 Years of Risankizumab Maintenance
Treatment in Patients with Moderate to Severe
Ulcerative Colitis Regardless of the Number of Prior
Advanced Therapy Exposures

E-Poster

17-20 October

PP1176

Efficacy and Safety of Upadacitinib Maintenance
Therapy in Moderately to Severely Active
Crohn's Disease: 144-Week Results From the U-
ENDURE Long-Term Extension Study

Oral

Monday, 19 October

11:30 – 12:30

OP108: Long term outcomes
of interventional trials in IBD

Effectiveness of Upadacitinib Treatment in
Moderate to Severe Crohn's Disease in Real-
World Clinical Practice: 6-Month Results From
the UPlift Study

Moderated poster

Sunday, 18 October

09:00 – 10:00

MP0015: Therapeutics in IBD - Real
world experience (3)

Comparative Health Care Resource Use and
Treatment Patterns Following Tumor Necrosis
Factor Inhibitor Cycling Versus Switching to
Upadacitinib: A Propensity Score Matched
Analysis

Oral

Tuesday, 20 October

14:30 – 15:30

OP292: Real world observations in IBD:
Things we don't see in clinical trials

ABBV-466, A Novel Dual-targeting Therapy,
Leads to Endoscopic Remission in Moderate-to-
severe Crohn's Disease: Primary Results and

Molecular Profiling from the Phase 2a TARGET-
CD study

Oral

Monday, 19 October

10:00 – 11:00

LB08: Late-Breaking IBD Trials 

SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally. 

About SKYRIZI®
SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.1 SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of moderately to severely active plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.1,2

On August 27, 2026, AbbVie announced submission of an application to the European Medicines Agency (EMA) seeking approval of SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.

EU Indications and Important Safety Information about SKYRIZI® (risankizumab)1 

Indications

Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Important Safety Information

Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis).

Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.

Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Prior to initiating therapy with risankizumab, completion of all appropriate immunizations should be considered according to current immunization guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.

The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).

Commonly (≥ 1/100 to < 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, eczema, fatigue, and injection site reactions.

This is not a complete summary of all safety information.

See Skyrizi full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu 

Globally, prescribing information varies; refer to the individual country product label for complete information.

About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.3,4 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.3

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.

EU Indications and Important Safety Information about RINVOQ® (upadacitinib)3

Indications

Rheumatoid arthritis
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis
RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Polyarticular juvenile idiopathic arthritis
RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) [polyarticular rheumatoid factor positive {RF+} or negative {RF-}, extended oligoarticular], in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis
Non-radiographic axial spondyloarthritis (nr-axSpA) 
RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Giant cell arteritis
RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

Atopic dermatitis
RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.

Alopecia areata
RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Vitiligo
RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Crohn's disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Important Safety Information

Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:

- 65 years of age and older;
- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);
- patients with malignancy risk factors (e.g. current malignancy or history of malignancy).

Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.

Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.

Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.

Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.

Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.

Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.

Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.

Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.

Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids). Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.

Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.

Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.

Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.

Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.

Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.

Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.

Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.

Medication residue in stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ tablets. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.

Giant cell arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.

Excipients with known effect
RINVOQ 1 mg/ml oral solution contains 0.3 mg sodium benzoate in each ml.

Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.

The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.

The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in paediatric patients with pJIA treated with RINVOQ was consistent with the known safety profile of RINVOQ.

The safety profile of RINVOQ 15 mg and 30 mg observed in patients with alopecia areata was generally consistent with the known safety profile in patients with atopic dermatitis.

The safety profile of RINVOQ 15 mg observed in patients with vitiligo was generally consistent with the known safety profile in patients with atopic dermatitis. A higher incidence of hypercholesterolemia was observed in patients with vitiligo treated with RINVOQ 15 mg compared to placebo.

The most common serious adverse reactions were serious infections.

The safety profile of RINVOQ with long term treatment was generally similar to the safety profile during the placebo-controlled period across indications.

RINVOQ is available in 15 mg, 30 mg, and 45 mg prolonged-release tablets and 1 mg/ml oral solution. RINVOQ tablets and RINVOQ oral solution are not bioequivalent. Refer to the Summary of Product Characteristics for posology and method of administration.

This is not a complete summary of all safety information.

See RINVOQ full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu 

Globally, prescribing information varies; refer to the individual country product label for complete information.

About TARGET-CD:
TARGET-CD (M24-885) is a global Phase 2a, multicenter, randomized platform study designed to evaluate multiple investigational targeted therapies, including monotherapy and combination approaches, in adults with moderately to severely active Crohn's disease. The innovative platform design enables evaluation of the efficacy, safety, and mechanistic profiles of different therapeutic strategies using a common comparator, with the goal of rapidly advancing new treatment approaches for patients with Crohn's disease. More information on the TARGET-CD trial can be found at www.clinicaltrials.gov (NCT06548542).

About ABBV-466:
ABBV-466 is an investigational dual-targeting therapy combining risankizumab, an IL-23 inhibitor, with trosunilimab, an α4β7 inhibitor, to address complementary drivers of inflammation in Crohn's disease. The approach is designed to inhibit inflammatory signaling while limiting immune-cell trafficking to the gut, with the goal of achieving deeper disease control than either pathway alone.

ABBV-466 is investigational and its safety and efficacy have not been established by regulatory authorities.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

SKYRIZI. Summary of product characteristics. AbbVie; 2026.
SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
RINVOQ. Summary of product characteristics. AbbVie; 2026.
Pipeline. AbbVie. 2026. Accessed September 24, 2026. https://www.abbvie.com/our-science/pipeline.html

SOURCE AbbVie

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigatge potential securities claims on behalf of shareholders of Azenta, Inc. (NASDAQ: AZTA) resulting from allegations that Azenta may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Azenta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/azenta-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On August 24, 2026, Azenta filed with the SEC a current report on Form 8-K which stated that on “August 22, 2026, John P. Marotta resigned as President and Chief Executive Officer of Azenta, Inc. (the “Company”) and as a member of the Company’s Board of Directors (the “Board”), effective as of August 22, 2026 (the “Effective Date”).”

On this news, Azenta’s stock fell 12% on August 24, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

On its third-quarter 2026 earnings call, held on Oct. 14, 2026, Fastenal (FAST +1.27%) announced that sales grew 15.5%, while earnings grew faster than sales. Market share gains in large-account contracts are driving durable operating leverage for the industrial distributor. Three takeaways from the call highlight how this model compounds.

Contract customers under multi-site supply agreements now represent over three-quarters of net sales. Fastenal is expanding daily sales with these larger sites faster than the broader industrial market.

Contract customers now represent over 76% of sales, and their daily sales grew 18.8%.
-- Jeffery Watts, President and Chief Executive Officer2. Digital Replenishment Technology Deepens Customer RetentionThe company continues to deploy Fastenal Managed Inventory (FMI), its digital vending and automated bin technology that streamlines customer supply chains. Moving customers to automated ordering embeds Fastenal into daily plant operations and improves fulfillment efficiency.

We need to keep moving customers toward technology-enabled replenishment because it improves service, it strengthens the relationship, and it creates efficiency for both sides.
-- Jeffery Watts, President and Chief Executive Officer3. Workflow Automation Generates Operating Expense LeverageSelling, general, and administrative (SG&A) operating expenses dropped as a percentage of sales because headcount grew less than 1% during the quarter. Specialized digital tools and branch automation allow local teams to manage larger accounts without adding extra personnel.

This reflects productivity, role specialization and the benefits of technology and automation.
-- Max Tunnicliff, Executive Vice President and Chief Financial OfficerLooking AheadIndustrial demand is expanding across heavy manufacturing and data center build-outs, and management isn't hiding its satisfaction with top-line momentum.

Industrial conditions improved further in the third quarter.
-- Max Tunnicliff, Executive Vice President and Chief Financial OfficerFastenal holds structural advantages in its captive delivery fleet, on-site inventory hubs, and digital integration tools. Management continues to focus on price/cost neutrality to balance pricing adjustments against product inflation.

New customer wins create embedded spend, technology deepens those relationships and our scale allows us to grow profitably while continuing to invest.
-- Jeffery Watts, President and Chief Executive OfficerThis article was created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. The Motley Fool has positions in and recommends Fastenal. The Motley Fool has a disclosure policy.